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DISSERTATION ABSTRACT 
 
Zachary Stephen Clayton 
 
Doctor of Philosophy 
 
Department of Human Physiology 
 
June 2018 
 
Title: The Role of Pik3r1 in the Regulation of Adipose Tissue Insulin Sensitivity 
 
 
Obesity is a burgeoning health crisis in the United States. Obesity is associated 
with an earlier and greater risk for developing metabolic diseases. Insulin resistance is a 
central and defining feature of the metabolic diseases associated with obesity.  
Class 1a Phosphatidylinositol 3-kinase (PI3K) is integral in canonical insulin 
signaling. PI3K contains regulatory (p85a/b, p55a/g, p50a) and catalytic (p110a/b/d) 
subunits. The a regulatory subunits are encoded by Pik3r1. Increased Pik3r1 abundance 
has been observed in obese white adipose tissue (WAT). Furthermore, obese mice with 
heterozygous (HZ) knockout of Pik3r1 remain insulin sensitive, despite marked obesity.  
Taken together, it is crucial to understand the role of WAT Pik3r1 in regulating 
insulin sensitivity. Recently, literature has demonstrated that standard vivarium 
temperature (~22°C) is a thermal stress for mice, as their thermoneutral zone is ~30°C. 
Considering mice are a preclinical model for studying metabolic disease, it is critical to 
understand cellular and systemic responses to high fat diet (HFD) at 22°C and 30°C.   
 To determine the role of AT Pik3r1 in regulating insulin sensitivity, mice with 
constitutive and inducible adipocyte specific hetero/homozygous knockout of Pik3r1 
were studied following acute (three days) and chronic (12 week) HFD, respectively. 
Furthermore, insulin sensitivity was assessed in mice with adipocyte specific 
 v 
 
overexpression (OX) of p55a. To determine the influence of short-term (8 and 12 days) 
thermoneutral housing on insulin sensitivity, mice were studied following one and five 
days of HFD at 22°C and 30°C (one week acclimation at 30°C prior to starting HFD). 
 Visceral WAT p85a abundance was increased (2-fold) following acute HFD in 
wild-type mice, with a parallel increase in systemic insulin resistance. HZ knockout of 
adipocyte Pik3r1 prevented acute HFD induced systemic insulin resistance. Furthermore, 
HZ knockout of adipocyte Pik3r1 reversed obesity induced glucose intolerance and 
enhanced systemic insulin sensitivity and adipocyte insulin signaling. Moreover, OX of 
adipocyte p55a enhanced (40%) glucose tolerance, energy expenditure (30%: light cycle; 
45%: dark cycle) and markers of AT thermogenesis in brown AT. Lastly, housing 
temperature had a significant impact on the cellular pathways that regulate glucose 
metabolism in response to HFD exposure. This dissertation includes previously published 
co-authored material. 
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
 
Introduction 
Obesity is a progressive disease that is a result of prolonged positive energy 
balance. The increased prevalence of obesity has directed attention on a worldwide 
problem that is one of surplus, rather than one of famine or virus. In the United States, 
obesity is a burgeoning health crisis, with only 30% of adults considered to be of ‘normal 
weight’  (16), and similar trends are being observed worldwide (1). Considering obesity 
increases the risk of complex and costly metabolic diseases including type 2 diabetes, 
cardiovascular disease, stroke and non-alcoholic fatty liver disease as well as certain 
cancers  (31), it is one of the greatest public health challenges in the United States  (14). At 
the turn of this century, 171 million individuals were estimated to have diabetes; this is 
expected to increase to 366 million by 2030 (46).  
Insulin resistance is a central and defining feature of obesity  (31) that is proposed 
to be a consequence of increased adipose tissue inflammation. Insulin resistance is defined 
as an inadequate response by insulin target tissues, such as skeletal muscle, liver, and white 
adipose tissue, to the physiologic effects of circulating insulin. The hallmarks of impaired 
insulin sensitivity in these three target tissues are decreased insulin-stimulated glucose 
uptake into skeletal muscle, impaired insulin-mediated suppression of hepatic glucose 
production, and a reduced ability of insulin to inhibit lipolysis and increase glucose uptake 
in adipose tissue. In type 2 diabetes, it has been widely established that insulin resistance 
precedes the development of evident hyperglycemia  (37). Thus, targeting interventions 
	 2 
that regulate insulin sensitivity may be crucial in preventing the progression of other 
metabolic diseases. 
Although the pathogenesis of insulin resistance in obesity is multifactorial, it is 
clear that chronic, low-grade inflammation is a major contributor, with the 
proinflammatory macrophage identified as the primary stimulus (28). Mechanistically, the 
current model for insulin resistance in obesity suggests that adipose tissue macrophage 
(ATM) infiltration and proinflammatory cytokine release activates inflammatory pathways 
such as inhibitor of kappa B kinase b (IKKb) and Jun NH2-terminal kinase (JNK), which 
impinge upon the insulin signaling cascade by inhibiting tyrosine phosphorylation of 
insulin receptor substrate 1 (IRS1), leading to impaired insulin activation of 
Phosphatidylinositol 3-Kinase (PI3K) and Akt (28).  
 PI3K, a heterodimeric enzyme composed of a regulatory subunit (p85a/b, p55a/g, 
p50a) and a catalytic subunit (p110a/b), is an essential component of the canonical insulin 
signaling cascade in adipose tissue (15). Insulin-stimulated PI3K activity is decreased in 
obese adipose tissue in parallel with a 1.5, 4, and 3 -fold increase in p85a, p55a and p50a 
abundance, respectively (26); heterozygous deletion of Pik3r1 limits regulatory subunit 
expression, enhances adipocyte insulin signaling and protects against adipose tissue 
macrophage accumulation (26). Additionally, genetic deletion of p55a/ p50a in mice has 
been shown to increase adipocyte insulin-stimulated glucose uptake and systemic insulin 
sensitivity (8).  
The developmental niche, anatomical distribution, and abundance of particular 
white adipose tissue depots have been shown to influence systemic glucose tolerance, 
insulin sensitivity and inflammation (32). Furthermore, brown fat and the propensity of 
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white adipose tissue to adopt a brown-like phenotype has been shown to influence systemic 
glucose tolerance and insulin sensitivity. Standard mouse vivarium temperature is set 
below the murine thermoneutral zone (30°C), which may be a thermal stress. Housing 
temperature has been shown to influence brown adipose tissue development, white adipose 
tissue browning, inflammation and energy expenditure. Thus, it is critical to understand the 
relationship between environmental temperature and adipose tissue browning, 
inflammation and insulin sensitivity. 
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Background and Significance 
Obesity and insulin resistance. 
In Western cultures, obesity is one of the most common acquired factors causing 
insulin resistance  (31). Glucose levels may remain relatively normal in an insulin resistant 
state due to the presence of a robust compensatory insulin secretory response. However, 
when insulin-producing pancreatic β cells can no longer compensate for the decreased 
tissue insulin sensitivity, glucose homeostasis deteriorates and impaired glucose tolerance 
and eventually type 2 diabetes develop. Insulin resistance is marked by impaired cellular 
insulin action in its target tissues (30). 
Obesity is a progressive disease that develops due to prolonged positive energy 
balance. Interestingly however, brief (3 and 7 d) caloric overfeeding rapidly induces 
systemic glucose intolerance and insulin resistance (22; 9; 45) independent of significant 
changes in body weight. Conversely, calorie restriction without significant changes in body 
weight, enhances skeletal muscle (7; 19) and liver  (19) insulin sensitivity. Thus, significant 
changes in insulin action can occur with small changes in energy balance, without 
substantial weight change, and within a relatively short period of time. The fact that insulin 
sensitivity can be modulated so quickly raises important questions, such as, why and how 
are these tissues so sensitive to slight perturbations in nutritional cues? 
In skeletal muscle and adipose tissue, an increase in insulin promotes glucose 
uptake by activating a complex cascade of signaling events (38; 41). Briefly, binding of 
insulin to the insulin receptor leads to downstream tyrosine phosphorylation of protein 
substrates that then engage and activate PI3K. This leads to downstream signaling through 
Akt, which results in GLUT4 translocation from its intracellular pool to the plasma 
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membrane and glucose transport into the cell  (41). In adipose tissue, insulin is also anti-
lipolytic, whereby it inhibits the release of fatty acids and glycerol from adipocytes by 
decreasing the activity of hormone-sensitive lipase  (11). In the liver, insulin decreases the 
release of glucose by inhibiting hepatic glycogenolysis (glycogen breakdown to glucose) 
and the expression of key gluconeogenic enzymes  (44). 
ii. White adipose tissue biology as it relates to obesity and insulin resistance. 
White adipose tissue was once thought to be strictly a sight for triacylglycerol 
storage and maintenance of energy equilibrium, but is now considered to function as an 
endocrine organ (43). Adipocyte functionality is lost during obesity and has been related 
to adipocyte hyptertrophy, imbalance between lipolysis and lipogenesis leading to 
lipotoxicity and an inability to respond to external signals, such as insulin (32). 
Furthermore, the specific site of white adipocyte dysfunction plays a significant role in the 
development of associated metabolic diseases (32).  
White adipose tissue develops in multiple discrete depots throughout the body. The 
most common classification scheme of white adipose tissue distinguishes between 
subcutaneous and visceral adipose tissue (32). There is a wealth of literature supporting the 
positive association of visceral adipose tissue with metabolic disease, whereas less is 
known about the role of subcutaneous adipose tissue, but it may be inversely related (21). 
Important to note, many adipose tissue depots in mice do not have defined correlates in 
humans, and vice versa; for example, visceral fat in humans is commonly stored in the 
omentum, which is hardly present in rodents. Conversely, the epididymal fat pads in male 
mice that are commonly assayed for visceral adipose tissue metabolism and inflammation, 
do not exist in humans (32).  
	 6 
Despite the distinctions between human and rodents, there are clearly regional 
differences in adipocyte function, such as secretory profiles and rates of insulin stimulated 
suppression of lipolysis and triglyceride storage (40). Two hypotheses have emerged as a 
means of explaining the differences between subcutaneous and visceral adipose tissue: 
either (1) each depot has a specific relationship with circulation or (2) physiology is 
predicated on cell autonomous differences. For example, gene signatures of pre adipocytes 
are specific to their tissue of origin, even after multiple passages (23; 39). Furthermore, 
transplantation studies have directly assessed this by placing visceral adipose tissue in the 
subcutaneous space, which had minimal effect, but transplantation of subcutaneous adipose 
tissue to the visceral space results in decreased adiposity and enhanced glucose metabolism 
(42). Taken together, there are clear molecular and physiological distinctions between 
visceral and subcutaneous adipose tissue, demonstrating the importance to study each 
depot individually when implementing interventions that have a profound effect on 
adiposity and glucose metabolism, such as high fat diet treatment.  
Recently, the developmental niche of adipose tissue has been a topic of 
investigation in an attempt to better understand the innate differences between the distinct 
depots. All adipocytes develop from pre-adipocytes, which initially develop from 
hematopoietic precursors (32). In a state of energy surplus, subcutaneous adipocytes 
expand through both hyperplasia and hypertrophy (17), while epididymal adipocytes 
expand strictly through hypertrophy (17). Relative to hyperplasia, adipocyte hypertrophy 
is associated with increased metabolic dysfunction due to larger adipocytes having greater 
rates of lipolysis, macrophage chemotaxis and insulin resistance (17). 
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Distinct from white adipose tissue, brown adipose tissue (BAT) is multilocular 
rather than unilocular, and shares a development lineage with skeletal muscle (originate 
from Pax7+/Myf5+ stem cells) and not WAT (originate from Pax7-/Myf5- stem cells)  (34). 
BAT has been highly studied as a therapeutic target to offset obesity due to expression of 
uncoupling protein-1 (UCP1), which circumvents ATP synthase to generate heat from 
glucose and lipid oxidation (20). UCP1 ablation induces obesity and abolishes diet-induced 
thermogenesis (13). BAT is positively associated with energy expenditure (5), glucose 
tolerance (36) and insulin sensitivity (36). Cold exposure in rodents has been shown to 
increase brown fat abundance, Ucp1 expression in brown and white adipose tissue and 
increase the number of multilocular cells in white adipose tissue (5). Interestingly, 
subcutaneous WAT appears to be more susceptible than epdidymal WAT to cold-induced 
browning (35). 
Taken together, it is clear there are cell autonomous roles of each adipose tissue 
depot (subcutaneous WAT, epididymal WAT and BAT), and it is imperative to understand 
these differences when studying adipose tissue. Furthermore, considering the adiponectin-
Cre mouse is commonly used to cross with transgenic and knockout (KO) mouse models 
to determine adipocyte specific roles of genes and proteins, it is important to be mindful 
that adiponectin is also expressed in BAT. Considering the dynamic role of BAT in 
regulating obesity and insulin sensitivity, BAT must not be overlooked when interpreting 
findings from AT specific OX and KO models.  
Adipocyte specific mouse models. 
The study of adipose tissue has been significantly advanced through use of 
genetic mouse models. The use of the Cre/lox system for gene targeting has 
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revolutionized the study of tissue specific functions in vivo. Cre recombinase may be 
integrated downstream of an endogenous promotor, or it can be placed under control of a 
promoter fragment which is then integrated into the genome at a random site. 
Additionally, temporal control over gene expression can be gained by use of tamoxifen-
sensitive Cre. When applying these techniques, it is imperative to keep in mind the 
limitations of these approaches including variable expression of Cre transgenes and the 
varying sensitivity of different genomic sites to Cre-mediated loxP recombination (5, 8).  
To facilitate the study of adipocyte specific functions in vivo, several adipocyte-
specific promotors have been generated to drive the expression of Cre recombinase in 
adipose tissue. Of these, commonly used Cre transgenes were generated from the 
promotor of the fatty acid binding protein 4 (Fabp4) gene which encodes adipocyte 
protein 2 (aP2) (3). However, aP2-Cre has been shown to have Cre activity in other 
tissues and cell types, including brain, endothelial cells, macrophages, adipocyte 
precursors and embryonic tissues (6, 7, 9, 12). The discovery of white adipose tissue’s 
capacity to secrete a variety of hormones, including adiponectin, has guided further 
development of adipocyte-specific Cre mouse models. Adiponectin has been shown to 
selectively localize to the adipocyte (1), making it a potential target for creating 
adipocyte-specific Cre mouse models. 
Adiponectin (encoded by Adipoq) has been used to generate Cre lines to study 
adipocyte function (13). These Adiponectin-Cre lines have been shown by multiple 
groups to be highly specific to adipose tissue (2, 6, 7). Utilization of the membrane-
Tomato/membrane-GFP (mT/mG) dual fluorescent reporter has been used to determine 
tissue specific recombination (4). Using the mT/mG further supported previous findings 
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(6, 7, 9, 12) that aP2-Cre does not label the majority of adipocytes in white adipose tissue 
depots (4). These data may be explained by a shift in the Cre expression pattern in these 
lines over generations (5), which demonstrates the need to monitor the level of 
recombination over time. Furthermore, these data highlight the importance of 
determining tissue specificity within any Cre model system. Alternatively, adipocyte 
specific recombination was shown in the Adipoq-Cre mouse line, when using the mT/mG 
reporter (4). Furthermore, the Adiponectin-CreER line was shown to be efficient in 
targeting adipocytes in an inducible manner (4). However, recent reports have shown 
adiponectin to also be expressed in intestinal epithelial paneth cells (11). 
When using constitutive Cre mouse models, the development of the target 
promotor must be considered to ensure developmental differences are considered when 
interpreting results. Adipoq-Cre is active during fetal inguinal white adipose tissue 
adipocyte differentiation and in fully mature adipocytes (not pre-adipocytes) in adult 
animals (10). Taken together, one should consider how the protein under investigation 
may influence adipocyte differentiation, if differences in adipose tissue mass and/or 
distribution are observed. 
Phosphatidylinositol 3-Kinase. 
Class 1a PI3K is lipid kinase that catalyzes the production of plasma membrane-
bound phosphatidylinositol-3,4,5-triphosphate from phosphatidylinositol-4,5-biphosphate 
(6). The enzyme contains a catalytic (p110 α, β, δ) and regulatory (p85α a/β, p55 α/ϒ, 
p50α) subunits. Class 1a regulatory subunits are encoded by the Pik3r1 gene. (Figure 1.) 
Of the Class 1a PI3K regulatory subunits, p85α is the most abundant  (12), thus it has 
historically been the primary focus of the studies assessing the role of the regulatory 
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subunits in insulin signaling (4; 18). Whole body knockout of p85α results in significantly 
improved systemic insulin sensitivity and protects against HFD induced insulin resistance  
(3; 27). Alternatively, increased expression of p85 α triggers severe insulin resistance  (3). 
Taken together, it is theorized that the regulatory subunits exist as either monomers or as 
heterodimers bound to the p110 catalytic subunit (p85-p110, p55-p110, p50-p110) (8; 24). 
During insulin stimulation, when functional PI3K heterodimers bind to Insulin Receptor 
Substrate-1 (IRS-1), normal insulin signaling occurs, however; the theory suggests that 
when monomeric regulatory subunits bind to IRS-1, insulin signaling is competitively 
inhibited (8; 24). Thus, excess regulatory subunits of PI3K may cause decreased insulin 
sensitivity and are indeed elevated in obese skeletal muscle and adipose tissue (2; 26). To 
date however, over-expression of the specific Class 1a PI3K regulatory subunits has not 
been directly tested in vivo. 
Clinical studies have shown a significant induction of p85α in skeletal muscle after 
as little as three days of positive energy balance with a parallel decrease in systemic insulin 
sensitivity as measured by hyperinsulinemic-euglycemic clamps (10). Moreover, three 
days of high-fat diet significantly impairs systemic glucose tolerance and insulin sensitivity 
in rodents, but the effect on PI3K is unknown (22). Alternatively, caloric restriction in 
rodents enhances skeletal muscle glucose transport in parallel with decreased abundance 
of p55α/p50α and enhanced PI3K activity (25; 33). Caloric restriction has also shown to 
significantly improve insulin-stimulated glucose uptake in primary adipocytes (29). Thus, 
perturbations in the PI3K ratio of regulatory to catalytic subunit abundance may be the 
molecular mechanism connecting cellular insulin sensitivity to cellular energy status.  
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Specific Aims 
AIM 1. Investigate in vivo if increased adipocyte pik3r1 abundance is necessary to 
drive adipocyte and systemic insulin resistance. The primary research question 
addressed in AIM1 is: Can heterozygous knockout of adipose tissue pik3r1 prevent 
initiation of adipose tissue insulin resistance with acute high-fat diet? 
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AIM 2. Investigate in vivo if temporal heterozygous knockout of adipocyte pik3r1 
reverses obesity induced insulin resistance and adipose tissue inflammation. The 
primary research question addressed in AIM2 is: Following the development of obesity, 
can heterozygous knockout of adipocyte pik3r1 reverse obesity induced insulin resistance, 
independent of weight and adiposity, as well as enhance adipocyte and systemic insulin 
sensitivity? 
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AIM 3. Investigate in vivo if adipocyte overexpression of PI3K p55alpha drives insulin 
resistance in lean mice. The primary research question addressed in AIM3 is: Is 
overexpression of adipocyte PI3K p55a sufficient to drive adipose tissue and systemic 
insulin resistance in chow fed mice, lean mice? 
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AIM4. Investigate the role of housing temperature in the regulation of glucose 
metabolism and markers of adipose tissue browning in response to short-term 
overfeeding in lean wild type mice. The primary research question addressed in AIM4 is: 
Does housing temperature influence glucose metabolism and inflammation following 
short-term high-fat diet feeding. 
 
 
	
Chapter V of this dissertation has previously been published. 
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CHAPTER II 
HETEROZYGOUS KNOCKOUT OF PIK3R1 PROTECTS AGAINST ACUTE 
HIGH FAT DIET INDUCED GLUCOSE INTOLERANCE AND INSULIN 
RESISTANCE 
Introduction 
Obesity and its reciprocal metabolic diseases are a burgeoning health crisis in the 
United States, with approximately 40% of US adults classified as obese (8). Insulin 
resistance, a central and defining component of obesity, has been identified as a primary 
contributor to the increase in a multitude of metabolic diseases (6). Brief (3 and 7 day) 
caloric overfeeding, resulting in a positive energy balance, rapidly induces systemic 
glucose intolerance and insulin resistance, independent of changes in body weight or 
adiposity (5; 9; 20). Thus, changes in insulin sensitivity can be modulated quickly, but 
the driving mechanism is unknown. Phosphotidylinositol 3-kinase (PI3K) is a critical 
node in canonical insulin signaling, and is essential for a multitude of cellular functions 
and is critical for nearly all of insulin’s metabolic actions including glucose transport, 
lipid metabolism, and glycogen and protein synthesis (3). In adipocytes, PI3K plays a key 
role in regulating insulin-stimulated glucose uptake and inhibition of lipolysis (15). A 
variety of impairments in the aforementioned PI3K-linked pathways are found in obesity 
(2; 12), suggesting PI3K plays a major role in the progression of insulin resistance.  
PI3K is an obligate heterodimer consisting of a regulatory subunit (p85a/b, p55a, 
p50a) and a catalytic subunit (p110a/b) (19). The regulatory subunits p85a, p55a, p50a 
are encoded by the Pik3r1 gene, while p85b is encoded by the Pik3r2 gene. Studies 
conducted in cell culture and transgenic mouse models have shown that complete 
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deletion of the regulatory isoforms (p85a only, p85b only, and p55a/p50a double 
knockout) or heterozygous (HZ) Pik3r1 deletion enhances PI3K activity and subsequent 
insulin sensitivity (4; 7; 18; 17; 12). Furthermore, inhibiting p85a expression improves 
insulin signaling and glucose homeostasis in obese mice (16), and mice with genetically 
induced insulin resistance via heterozygous deletion of the insulin receptor (IR) or insulin 
receptor substrate-1 (IRS1) (11).  Global HZ knockout of Pik3r1, but not Pik3r2, has 
been shown to enhance PI3K enzyme activity and improve systemic and adipocyte 
insulin sensitivity, despite marked obesity (12). Taken together, there is a clear link 
between adipose tissue Pik3r1 abundance and insulin sensitivity. 
Here, we investigated the hypothesis that adipocyte specific HZ knockout of 
Pik3r1 maintains glucose tolerance and systemic insulin sensitivity, following three-day 
HFD treatment. To accomplish this, we studied free living metabolic profiles, glucose 
tolerance and systemic insulin sensitivity in mice with adipocyte specific 
hetero/homozygous knockout of Pik3r1 under the control of the constitutive adiponectin 
promoter. Our results demonstrate that HZ mice, but not KO, maintain glucose tolerance 
and insulin sensitivity following three-day HFD treatment. Furthermore, KO mice 
demonstrate decreased energy expenditure during the light and dark cylces, independent 
of diet treatment. Together, these data support the notion that adipose tissue PI3K is a key 
step in regulating energy and glucoses homeostasis, as well as insulin sensitivity. 
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Methods 
Experimental Design. All experiments were approved by Institutional Animal Care 
and Use Committee at the University of Oregon. Mice with a mixed B6/129S background 
and homozygous for loxP sites flanking exon 8 of the Pik3r1 gene (Pik3r1tm1Lca/J; Jackson 
Laboratory, #012871) (Pik3r1 flox) were used in these studies. Mice with the targeted allele 
compared to wild type show no difference p85α abundance in the absence of recombinant 
cre (1, 10). To generate mice with adipocyte specific hetero/homozygous knockout of 
Pik3r1, we crossed Pik3r1 flox mice with mice expressing Cre recombinase (Cre) under 
the control of the adipose tissue adiponectin promoter (adipo Cre). After Cre-mediated 
recombination, exon8 of the Pik3r1 gene is cleaved, specifically in adipocytes. Pik3r1 flox 
mice that lacked adipo Cre are referred to herein as wild-type (WT) and were used as 
controls for all studies. All mice were housed at standard vivarium temperature (22°C) with 
a 12:12-h light-dark cycles (Light Cycle: 6:00- 18:00; Dark Cycle: 18:00-6:00) and fed 
chow diet with 13% fat (Picolab Rodent Diet 20; LabDiet) until 10 weeks of age. At ten 
weeks of age, male mice were singly housed in standard-sized cages and placed within an 
environmental cabinet set to mouse thermoneutral temperature (30°C) and fed a control 
diet (CON: 10% Calories from fat; 3.85 kcals/g, D1245OH, Research Diets, New 
Brunswick, NJ) for one week. After a one week acclimation period, mice were randomly 
assigned to remain on the CON diet or were provided a high fat diet (HFD; 45% Calories 
from fat; 4.73 kcals/g, D12451, Research Diets, New Brunswick, NJ). Both the CON and 
HF diets were matched for sucrose (17%).  
Body Composition. Body composition (lean tissue, fat and free fluid) was measured 
by time domain (TD)-NMR using the Minispec LF50 mouse NMR (Bruker BioSpin, 
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Billerica MA, state) in un-anaesthetized mice before and after the 3 day period. Percentages 
were calculated from body weight measured on a standard scale (Mettlor-Toledo, 
Columbus, OH) using the Minispec Software.  
Food Intake and Total Energy Expenditure. Using a metabolic monitoring system 
(Promethion, Sable Systems, Las Vegas, NV), we measured cage behavior (food intake, 
water intake and activity), oxygen, carbon dioxide and water vapor during the 12:12-h 
light-dark cycles (Light Cycle: 6:00- 18:00; Dark Cycle: 18:00-6:00) following three full 
light and dark cycles. The metabolic cages were kept inside an environmental cabinet 
allowing temperature control throughout the study. Metascreen software (Sable Systems 
Inc.) was used for data collection and data was processed with ExpeData (Sable Systems 
Inc.) proprietary macros. Energy expenditure (kcals/hour) was calculated relative to 
bodyweight (kg). Food intake (g/day) was converted to kcals/day and made relative to 
bodyweight (kg). 
Oral Glucose Tolerance Test. Glucose tolerance tests were performed in conscious 
mice following 3d diet treatment. Mice were fasted for 4 h (6-10 AM) before testing to 
normalize glucose and insulin levels. Tails were nicked with sterile scissors and ~2-5 μl of 
blood was analyzed with a handheld glucometer (Bayer Contour). After the fasting glucose 
measurements, the animals were given 5g/kg bodyweight dextrose by oral gavage. Glucose 
was measured again at 10, 20, 30, 45, 60, 75, 90 and 120 minutes. Glucose area under the 
curve (AUC) was calculated from baseline glucose values using GraphPad Prsim 7.0. 
Insulin Tolerance Test. Insulin tolerance tests were performed in conscious mice 
following the 3d diet treatment. Mice were fasted for 4h (6-10 AM) before testing to 
normalize glucose and insulin levels. Tails were nicked with sterile scissors and ~2-5 μl of 
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blood was analyzed with a handheld glucometer (Bayer Contour). After the fasting glucose 
measurements, the animals received an intraperitoneal (I.P.) injection of 0.25 U insulin 
(Humulin-R, Eli Lilly and Company, Indianapolis, IN)/kg bodyweight. Glucose was 
measured from tail blood again at 10, 20, 30, 40, 50 and 60 minutes. 
Immunoblotting. Perigonadal eWAT was homogenized with a BDC 2002 (Compact 
Digital, Caframo Lab Solutions, Ontario, Canada) at 100mg tissue/ 300µL of 
homogenization buffer (20mM Tris-HCl pH 7.4, 150mM NaCl, 1% Igepal/NP-40, 20mM 
NaF, 2mM EDTA pH 8.0, 2.5mM NaPP, 20mM β-glycerophosphate, 10% glycerol with 
added protease inhibitors (1mg/mL Aprotinin, 1mg/mL Leupeptin, 1mg/mL Pepstatin, 
6mg/mL Pefabloc SC, Phosphatase Inhibitor Cocktail 2 and 3 (Sigma Aldrich, San Jose, 
CA)). Samples were solubilized at 4°C for 1 hour with rotation and centrifuged at 4°C at a 
speed of 12,000 x g for 15min. Protein abundance was measured by bicinchoninic acid 
(BCA) assay (Thermo Fisher Scientific, Eugene, OR). Target proteins were measured in 
tissue homogenates (1 mg/mL) by capillary electrophoresis using a Wes instrument 
(Protein Simple, Biotechne) with PI3-Kinase p85 (1:25, ABS233; EMD Millipore; 
Burlington, MA) and with GAPDH (1:1K, 25778; Santa Cruz Biotechnology; Santa Cruz, 
CA) as a loading control. Data was quantitated using Compass Software (Protein Simple, 
Biotechne) with target proteins expressed relative to the loading control.  
Statistical Analysis.  Data were analyzed by a two-way analysis of variance 
(ANOVA) for main effects of diet and genotype except for the oral glucose tolerance test, 
which used a repeated measures 2-way ANOVA for main effects of group and genotype. 
A Sidak’s multiple comparisons post hoc test was performed when significant main effect 
differences were detect using a p-value of < 0.05. All data are presented as the mean ± 
	 20 
standard error of the mean (SEM). Statistics were calculated using Graph Pad Prism 
version 7 (Graph Pad Software; La Jolla, CA).  
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Results 
Hetero and homozygous knockout of adipocyte Pik3r1 exacerbates three-day high 
fat diet induced increases in body weight and adiposity. KO mice had a 7.5-fold decrease 
in eWAT p85a abundance relative to WT, while no difference was detected between WT 
and HZ mice (Fig. 1A). Relative to WT, body weights of HZ and KO mice following 
CON and HFD diet treatment were 20% and 25% higher, respectively. Furthermore, HZ 
and KO mice had a 9% increase in body weight between CON and HFD, while no 
difference was detected in WT mice (Fig. 1B). No differences in percent fat mass were 
detected between genotypes following CON diet treatment; however, relative to WT, HZ 
and KO mice had a 30% increase in percent fat mass following HFD treatment. 
Furthermore, HZ and KO mice had a 50% and 30% increase in percent fat mass between 
CON and HFD, respectively, while no difference was detected in WT mice (Fig. 1C). No 
differences in inguinal scWAT mass were detected between genotypes following CON 
diet treatment; however, relative to WT, HZ and KO mice had 25% greater inguinal 
scWAT mass following HFD treatment. No within genotype diet differences were 
detected in scWAT mass (Fig. 1D). Perigonadal eWAT mass increased in KO mice, 
relative to WT and HZ, independent of diet (Fig. 1E). Furthermore, KO mice had 20% 
lower brown AT (BAT) mass, independent of diet treatment. 
Heterozygous and homozygous knockout of adipocyte Pik3r1 alters the mouse 
behavior and the metabolic and circadian response to HFD. Mouse feeding behavior was 
changed by both diet and genotype. Specifically, relative to WT and KO mice on CON, 
HZ CON mice had 2.6 and 1.5-fold greater food intake, respectively (Fig. 2A). Relative 
to WT and KO mice on HFD, HZ mice had 1.5 and 1.8-fold greater food intake, 
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respectively (Fig. 2A). During the dark cycle, WT mice had 1.8-fold greater food intake 
following HFD treatment (Fig. 2B). Furthermore, relative to WT and HZ mice, KO mice 
had 1.2-fold greater food intake following CON diet treatment during the dark cycle (Fig. 
2B). RER was lower in WT, HZ and KO mice on HFD during the light cycle (WT: 
0.90±0.10 vs. 0.80±0.10; HZ: 0.89±0.20 vs. 0.83±0.10; KO: 0.88±0.10 vs. 0.81±0.20) 
(Fig. 2C). RER was lower in WT, HZ and KO mice on HFD during the dark cycle 
(WT:0.91±0.01 vs. 0.82±0.01; HZ: 0.94±0.01 vs. 0.81±0.01; KO: 0.90±0.01 vs. 
0.81±0.02) (Fig. 2D). Furthermore, relative to WT and KO mice on CON diet, HZ mice 
on CON diet had greater RER (HZ:0.94±0.01 vs. WT:0.91±0.01 and KO:0.90±0.01) 
(Fig. 2D).  There were no differences in total activity during the light cycle by diet or 
genotype (Fig.2, E-F). Relative to WT and HZ mice on HFD, energy expenditure was 
40% lower in KO mice on HFD during the light cycle (Fig.2, G).  Furthermore, relative 
to WT and HZ mice on CON and HFD, energy expenditure was 30% lower in KO mice 
during the dark cycle (Fig.2, H). 
Glucose intolerance and insulin resistance is associated with perigonadal eWAT 
p85a abundance. Following 3d HFD treatment, there was a 2-fold increase in 
perigonadal eWAT p85a abundance in WT mice (Fig. 3A). Relative to CON, fasting 
blood glucose increased following 3d HFD treatment, by 20% and 25% in WT mice and 
KO mice, respectively (Fig. 3B). Following CON diet treatment, fasting blood glucose 
was 20% higher in HZ mice, relative to WT (Fig. 3B). Furthermore, following HFD 
treatment, fasting blood glucose was increased by 16% in KO mice, relative to WT and 
HZ mice (Fig. 3B). Relative to CON, glucose clearance was reduced at the 20, 30, 45, 60, 
75, 90 and 120-minute time-points during a two-hour oral glucose tolerance test in WT 
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mice following HFD treatment (Fig. 3C). No differences in glucose clearance were 
detected at any time-point in HZ mice following HFD treatment, relative to CON (Fig. 
3D). Glucose clearance was reduced at the 30, 45, 60, 75, 90 and 120  minute time-points 
during a two hour oral glucose tolerance test in KO mice following HFD treatment, 
relative to CON (Fig. 3E). Glucose area under the curve, calculated from oral glucose 
tolerance tests, was increased by 1.5 and 2.2-fold in WT and KO mice, respectively, 
following HFD treatment (Fig. 3F). Following HFD treatment, insulin induced decrease 
in blood glucose was reduced at 40, 50 and 60 minutes, throughout a one hour insulin 
tolerance test, in WT mice (Fig. 3G). No differences in insulin tolerance were detected in 
HZ mice following HFD treatment (Fig. 3H). Insulin induced decrease in blood glucose 
was reduced at 40, 50, 60 minutes throughout a one hour insulin tolerance test, in KO 
mice following HFD treatment (Fig. 3I). 
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Discussion 
The most salient findings of this study are that HZ mice maintain glucose 
tolerance and insulin sensitivity following three day HFD treatment, despite having 
marked increases in body weight and percent fat mass. Furthermore, KO mice had 
decreased BAT mass and energy expenditure which was associated with an exacerbated 
glucose intolerant phenotype. This is the first study to assess the effect of adipocyte 
specific hetero/homozygous knockout of Pik3r1 on the regulation of in vivo energy 
homeostasis, glucose metabolism and insulin sensitivity following acute HFD treatment. 
Acute HFD treatment had a significant and rapid impact on the phenotype and 
metabolism of the mice, which was in part influenced by AT Pik3r1 expression. 
Specifically, AT Pik3r1 expression influenced food intake, energy expenditure and RER 
resulting in altered fat accretion and adipose tissue distribution. KO mice had decreased 
food intake during light cycle, independent of diet treatment, which was likely to offset 
the decreased energy expenditure observed during the light cycle. During the dark cycle, 
normal circadian patterns (elevated food intake, activity and energy expenditure) are 
disrupted in KO mice. Recent literature suggests PI3K regulates BMAL1/CLOCK-
mediated circadian transcription, (13) thus KO of PI3K could disrupt normal rhythmicity 
of these genes. Furthermore, HZ mice had elevated RER following CON diet treatment 
during the dark cycle, which is most likely due to elevated fasting blood glucose 
observed in HZ mice following the CON diet. KO mice had decreased energy 
expenditure at both the light and dark cycles, independent of differences in total activity, 
which is aligned with previous finding in mice with adipose tissue specific knockout of 
	 25 
PI3K p110a (14). In further support of the observed energy expenditure phenotype in KO 
mice, KO mice had decreased BAT mass, relative to WT and HZ mice, independent of 
diet. Taken together, it is clear that PI3K is critical for maintaining energy homeostasis. 
Increased perigonadal eWAT p85a abundance in WT HFD treated mice was 
associated with impaired glucose tolerance and insulin sensitivity. These data are similar 
to what has been previously shown in obese mice, in which obesity decreased insulin-
stimulated eWAT PI3K enzyme activity and glucose uptake (12). HZ mice in the present 
study were protected from HFD induced impairments in glucose tolerance and insulin 
sensitivity, which is aligned with previous findings in obese mice with whole-body HZ 
knockout of Pik3r1 (aHZ) (12). eWAT p85a abundance was not increased in aHZ mice, 
which was associated with maintained insulin-stimulated eWAT PI3K enzyme activity 
and glucose uptake, despite marked obesity (12). Thus, there is a clear connection 
between adipose tissue Pik3r1 expression, glucose homeostasis and insulin sensitivity. In 
the present study, we reason that the glucose intolerant phenotype was exacerbated by 
adipose tissue KO following HFD treatment, most likely due to impaired PI3K enzyme 
activity. PI3K functions as a heterodimer, in which the a regulatory subunits all contain 
bindings sites for the p110a catalytic subunit (3). The regulatory subunits also contain an 
inter-SH2 (iSH2) domain which recognize upstream phosphorylated tyrosine residues on 
insulin receptor substrate-1 (IRS-1) (3). Taken together, by lacking both the catalytic 
subunit binding domains and iSH2 domains, PI3K enzyme activity would be impaired in 
Pik3r1 KO mice and result in decreased glucose uptake in adipose tissue, and ultimately 
decreased glucose clearance overall.  
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From the data presented here, it is evident that glucose intolerance and insulin 
resistance can occur rapidly, and prior to a significant gain in body weight and adiposity. 
Furthermore, adipocyte Pik3r1 undoubtedly plays a role in regulating systemic glucose 
homeostasis and energy balance; thus, Pik3r1 may be used as a therapeutic target to 
attenuate the progression of metabolic diseases brought about by increased gain in weight 
and adiposity.  
To follow up on the results presented here and to determine the role of adipocyte 
Pik3r1 in regulating adipose tissue insulin sensitivity and insulin signaling, future 
experiments should assess insulin stimulated suppression of plasma glycerol to assess 
adipocyte insulin sensitivity as well as insulin activation of Insulin receptor substrate-1(p-
Y896), Akt (s473) and Hormone Sensitive Lipase (s660). By addressing these questions, 
we will be able to determine whether differences in systemic glucose metabolism are 
associated with specific differences in adipose tissue insulin sensitivity. 
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CHAPTER III 
 
INDUCIBLE HETEROZYGOUS KNOCKOUT OF ADIPOCYTE PIK3R1 
REVERSES OBESITY INDUCED GLUCOSE INTOLERANCE AND ENHANCES 
ADIPOCYTE INSULIN SENSITIVITY 
 
Introduction 
 
Obesity is a growing health crisis in the United States, with ~40% of adults 
classified as obese  (6). Obesity is associated with an earlier and greater risk for 
developing hypertension, coronary heart disease, type 2 diabetes and certain cancers (4). 
Treating obesity and its associated complications costs ~$230 billion/year, and 
startlingly, this economic burden is anticipated to more than double in the next 25 years 
(20). Insulin resistance is a central and defining feature of the metabolic diseases 
associated with obesity (5). Much attention has focused on the role of immune cells in 
exacerbating insulin resistance in obesity (15). However, therapies that chronically target 
the immune system in order to improve insulin sensitivity could have unwanted 
consequences on overall health, such as reducing one’s ability to fight infection (7). 
Furthermore, enhancing insulin sensitivity, independent of bodyweight, has been shown 
to reduce the incidence of metabolic diseases (17).  
Phosphatidylinositol 3-kinase (PI3K) is an essential component of insulin 
signaling, and is comprised of regulatory subunits (p85, p55, p50) and a catalytic subunit 
(p110) (2). In insulin activated cells, the regulatory-catalytic complex recognizes 
phospho-tyrosines (insulin receptor and insulin receptor substrate-1) by means of the Src 
homology 2 (SH2) domains in the regulatory subunits, which bring the p110 catalytic 
subunit in proximity to its lipid substrates. PI3K then catalyzes the reaction of PI-3,4,5-
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triphosphate (PIP3) from PI-4,5-bisphosphate (PIP2). PIP3 recruits PDK-1 (3-
phosphoinositide-dependent protein kinase) and mTORC2 (mammalian target of 
rapamycin complex 2) to the plasma membrane, which activate Akt, which, depending on 
the cell type, has a multitude of downstream effects (2). In adipose tissue, insulin 
signaling results in glucose uptake and inhibition of lipolysis (13).  
PI3K signaling is required for several key inflammatory functions, including 
cytokine production, proliferation and chemotaxis (14). PI3K activity is decreased in 
obese adipose tissue, which has been associated with increased NFkB activation and 
cytokine secretion  (11). Inversely, maintaining PI3K activity in adipose tissue, despite 
marked obesity, has been shown to reduce NFkB activation and cytokine secretion (11). 
 The Pik3r1 gene encodes the p85a, p55a, p50a isoforms of the regulatory 
subunits (2). It is well documented that global knockout of p85a (1) or p55a and p50a 
(3) improves insulin action in mice. However, there is no difference in insulin sensitivity 
in mice with liver specific deletion of Pik3r1 (19) and mice with skeletal muscle specific 
deletion of Pik3r1 have impaired insulin sensitivity (9). Furthermore, global deletion of 
the PI3K catalytic subunit has opposite effects on insulin sensitivity, relative to deletion 
of the regulatory subunit (1). Moreover, global heterozygous knockout (aHZ) of Pik3r1 
protects against obesity induced systemic and tissue specific insulin resistance, as well as 
adipose tissue inflammation, despite marked obesity (11). Interestingly, aHZ mice are 
protected against obesity induced insulin resistance in both adipose tissue and skeletal 
muscle. Considering adipose tissue inflammation is proposed to contribute to skeletal 
muscle insulin resistance (15), it is necessary to understand the independent role of 
adipose tissue Pik3r1 in obesity.  
	 29 
Here, we investigated the hypothesis that inducible heterozygous knockout of 
adipocyte Pik3r1 would reverse obesity induced insulin resistance, enhance adipocyte 
insulin signaling and decrease the abundance of pro-inflammatory immune cells in white 
adipose tissue. To do this, we studied adipose tissue immune cell infiltration and cytokine 
profiles, systemic glucose tolerance and insulin sensitivity, adipocyte insulin sensitivity 
and adipocyte insulin signaling in a mouse model with inducible adipocyte specific 
hetero/homozygous knockout of Pik3r1. Our results demonstrate that glucose intolerance 
is reversed following aHZ knockout of adipocyte Pik3r1. Furthermore, systemic insulin 
sensitivity, adipocyte insulin sensitivity and adipocyte insulin signaling are enhanced in 
obese HZ mice.  
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Methods 
Mouse model. All experiments were approved by and conducted in accordance 
with the Animal Care Program at the University of Oregon. All studies were conducted in 
male mice on a C57BL/6J background. To generate inducible adipocyte (iAdipo) specific 
Pik3r1 hetero/homozygous knockout mice, mice with a mixed B6/129S background and 
homozygous for loxP sites flanking exon 8 of the Pik3r1 gene (Pik3r1tm1Lca/J; Jackson 
Laboratory, #012871) were crossed with Adipo-CreERT2 (graciously donated by Dr. 
Stefan Offeremans) (16). To manipulate adipocyte Pik3r1 expression, 100µL of 
tamoxifen was administered daily for five consecutive days, at a dose of 10 mg/mL 
(resuspended in peanut oil) via oral gavage. Cre negative flox/flox mice also received 
tamoxifen, and were used as controls for the study.  
Experimental Design. At eight weeks of age, mice were individually housed at standard 
vivarium temperature (22-23°C) with access to nesting material and randomized to the 
control (CON: 10% Calories from fat; 3.85 kcals/g) (D1245OH, Research Diets, New 
Brunswick, NJ) or high-fat diet (HFD; 45% Calories from fat; 4.73 kcals/g) (D12451, 
Research Diets, New Brunswick, NJ) group. Following 10 weeks of diet treatment, mice 
underwent an oral glucose tolerance test (details described below), which served as 
assessment of obesity induced glucose intolerance. All mice were then administered 
tamoxifen (100µL; 10 mg/mL) for five consecutive days. From 19-20 weeks of age, mice 
remained on the assigned diet and were transferred to our metabolic monitoring system 
(Promethion, Sable Systems, Las Vegas, NV), which was set to 30°C, void of nesting 
material. This week served as an acclimation period to the new living conditions. One to 
two weeks following the final dose of tamoxifen, we determined total energy expenditure 
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during the 12:12-h light-dark cycles (Light Cycle: 6:00-18:00; Dark Cycle: 18:00-6:00) by 
monitoring oxygen consumption and carbon dioxide production. The metabolic monitoring 
system is within a thermal cabinet, allowing us to monitor mice throughout the experiment. 
We then conducted follow up OGTT experiments two weeks following the final dose of 
tamoixfen, as well as other metabolic testing (details described below) to determine the 
role of hetero/homozygous knockout of adipocyte Pik3r1 in obesity induced glucose 
intolerance. Between one and two weeks from the final dose of tamoxifen, mice were 
euthanized by cervical dislocation following isolfluorane anesthesia between 10am and 
1pm and tissues (inguinal scWAT, interscapular BAT and perigonadal eWAT) were 
rapidly dissected, snap-frozen in liquid nitrogen and stored at -80°C until analysis. 	
Metabolic Monitoring. Throughout these studies, the thermal cabinet remained set 
to 30°C, void of nesting material. Food intake, total activity, and energy expenditure were 
assessed following three full light and dark cycles. The measures of O2 consumption and 
CO2 production were used to calculate energy expenditure and the respiratory exchange 
ratio (RER), which is an index of the relative reliance on carbohydrate vs. fat oxidation. 
Metascreen software (Sable Systems Inc.) was used for data collection and data was 
processed with ExpeData (Sable Systems Inc.) proprietary macros. Energy expenditure 
(kcals/hour) was calculated relative to bodyweight (kg). Food intake (g/day) was 
converted to kcals/day and made relative to bodyweight (kg). 
Oral Glucose Tolerance Tests. Glucose tolerance tests were performed in 
conscious mice prior to tamoxifen administration, and following the three day data 
collection period in the metabolic monitoring system. Mice were fasted for 4 h (6-10 
AM) before testing, to normalize glucose and insulin levels. Tails were nicked with 
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sterile scissors and ~2-5 μl of blood was analyzed with a handheld glucometer (Bayer 
Contour). After the fasting glucose measurements, the animals were given 5g/kg 
bodyweight dextrose by oral gavage. Glucose was measured again at 10, 20, 30, 45, 60, 
75, 90 and 120 minutes. Glucose area under the curve (AUC) was calculated from 
baseline glucose values. 
Insulin Tolerance Test. Insulin tolerance tests were performed in conscious mice 
following the 1d and 5d diet treatment. Mice were fasted for 4h (6-10 AM) before testing 
to normalize glucose and insulin levels. Tails were nicked with sterile scissors and ~2-5 μl 
of blood was analyzed with a handheld glucometer (Bayer Contour). After the fasting 
glucose measurements, the animals received an intraperitoneal (I.P.) injection of 0.25 U 
insulin (Humulin-R, Eli Lilly and Company, Indianapolis, IN)/kg bodyweight. Glucose 
was measured from tail blood again at 10, 20, 30, 40, 50 and 60 minutes. 
Insulin Suppression of Plasma Glycerol. Mice were fasted for 4h (6-10AM). 
Following the 4h fasting period, venous blood was collected from the tail vein through an 
EDTA coated capillary tube, transferred to EDTA coated blood collection tubes and 
stored on ice. Mice were then received an IP injection of 1.0 U/kg insulin (Humulin), and 
a second blood sample was collected 15 minutes following insulin injection. Plasma was 
separated by spinning tubes at 12,000 x g for 15 minutes at 4°C. Glycerol was assessed 
by colorimetric assay as previously described (11). 
Adipocyte Insulin Signaling. Primary adipocytes were isolated from perigonadal 
eWAT by collagenase (1 mg/mL) digestion (10). Digest was passed through a 100µM filter 
and spun at 150 x g for 5 minutes. The floating adipocyte layer was carefully removed and 
resuspended in AT wash buffer (1:10 adipocytes: wash buffer) (10). Two tubes (basal and 
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insulin-stimulated conditions) per mouse, of isolated adipocytes (100 µL packed cell 
volume per tube) were incubated for two hours at 37°C in AT wash buffer (buffer described 
in (10)), with light rocking. Following the two-hour incubation, cells were treated with 
(insulin-stimulated condition) or without (basal condition) 1.2nM insulin for 5 minutes and 
immediately flash frozen.  
Immunoblotting. Adipocytes were homogenized with a BDC 2002 (Compact 
Digitial, Caframo Lab Solutions, Ontario, Canada) at 1:1 cell volume/ homogenization 
buffer (20mM Tris-HCl pH 7.4, 150mM NaCl, 1% Igepal/NP-40, 20 mM NaF, 2mM 
EDTA pH 8.0, 2.5mM NaPP, 20mM b-glycerophosphate, 10% glycerol with added 
protease and phosphatase inhibitors (1 mg/mL Aprotinin, 1 mg/mL Leupeptin, 1 mg/mL 
Pepstatin, 6 mg/mL Pefabloc SC, Phosphatase Inhibitor Cocktails 2 and 3 (Sigma 
Aldrich)). A bicinchoninic acid (BCA) assay was ran on individual tissue lysates and 1 
mg/mL was loaded per lane on the WES (Protein Simple). Antibodies: 1:25 PI3K p85a 
(Millipore Sigma ABS233); 1:25 pIRS1 Y896 (Abcam ab46800); 1:25 total IRS1 (Cell 
Signaling 2382); 1:25 pAkt S473 (Cell Signaling 9271); 1:25 pan Akt (Cell Signaling 
4691) 1:1K GAPDH (Millipore Sigma G9545). 
Statistical Analysis.  Data were analyzed by a two-way analysis of variance 
(ANOVA) for main effects of diet and genotype except for the oral glucose tolerance test, 
which used a repeated measures 2-way ANOVA for main effects of group and genotype. 
A Sidak’s multiple comparisons post hoc test was performed when significant main effect 
differences were detect using a p-value of < 0.05. All data are presented as the mean ± 
standard error of the mean (SEM). Statistics were calculated using Graph Pad Prism 
version 7 (Graph Pad Software; La Jolla, CA).  
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Results  
Validation of inducible adipocyte Pik3r1 KO mouse. Following tamoxifen 
treatment, there is a 5-fold decrease in WAT adipocyte p85a and p55a protein 
abundance in KO mice, relative to WT (Fig. 1A). There is no difference in WAT 
adipocyte p85a and p55a protein abundance between WT and HZ mice (Fig. 1A). 
Furthermore, there is no difference in p85a protein abundance between WT, HZ and KO 
WAT SVF (Fig. 1B), gastrocnemius (Fig. 1C) and liver (Fig. 1D).  
Body weight and body composition in CON and HFD fed WT, HZ and KO mice 
following tamoxifen treatment. Body weight (Fig. 2B), percent fat mass (Fig. 2C), 
perigonadal eWAT mass  (Fig. 2D) and scWAT mass (Fig. 2E) significantly increased 
following 12 weeks of HFD in WT, HZ and KO mice. Interscapular BAT mass increased 
with 12 weeks HFD only in WT and KO  mice (Fig. 2F). No differences between 
genotypes were detected following CON treatment. 
Adipocyte Pik3r1 HZ and KO alters mouse behavior as well as the metabolic and 
circadian response to HFD. Mouse feeding behavior was changed by HFD, but there 
were no differences between genotypes. Specifically, HFD resulted in greater food intake 
across all genotypes in the light cycle (Fig. 3A); however, food intake only increased in 
HFD fed KO mice  during the dark cycle (Fig. 3B). There was a significant effect of diet 
and genotype in assessment of RER during the light and dark cycles (Fig. 3, C-D). 
During the light cycle, RER was higher in KO mice on CON relative to HFD (0.90±0.04 
vs. 0.80±0.02), while this difference was not observed in WT and HZ mice. During the 
dark cycle, RER was higher in HZ and KO mice on CON, relative to HFD (HZ: 
0.88±0.05 vs. 0.75±0.02; KO: 0.88±0.03 vs. 0.80±0.03), while no difference was 
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observed in WT. No differences between diet or genotype were observed in total activity 
during the light cycle (Fig. 3E). During the dark cycle, total activity was higher in KO 
mice on CON, relative to WT; however, no differences were observed in total activity 
throughout HFD feeding (Fig. 3F). No differences in energy expenditure were observed 
between diet or genotype during the light and dark cycles (Fig. 3, G-H). 
Inducible HZ knockout of adipocyte Pik3r1 reverses obesity induced glucose 
intolerance. Following 10 weeks of HFD, prior to tamoxifen treatment 
(hetero/homozygous knockout of adipocyte Pik3r1), glucose intolerance was 
significantly increased in all mice, regardless of genotype (Fig. 4, A-D). Following 
hetero/homozygous knockout of adipocyte Pik3r1, glucose intolerance was ameliorated 
in HFD fed HZ mice, but not in HFD fed WT or KO mice, despite no improvement in 
fasting glucose (Fig. 4, E-H).  
Inducible heterozygous knockout of adipocyte Pik3r1 improves systemic and 
adipocyte insulin sensitivity. Following hetero/homozygous knockout of adipocyte 
Pik3r1, HZ mice are protected from obesity induced impairments in insulin tolerance, 
which was not observed in obese WT and KO mice (Fig. 5, A-D). Furthermore, HZ mice 
are protected against obesity induced impairments in adipocyte insulin sensitivity, as 
measured by insulin-stimulated stimulated suppression of plasma glycerol. This 
protective phenotype was not observed in in obese WT and KO mice (Fig. 5E).  
Inducible heterozygous knockout of adipocyte Pik3r1 influences adipocyte insulin 
signaling upstream and downstream of PI3K. Adipocyte insulin-stimulated 
phosphorylation of IRS1(Y896) and Akt(S473) were reduced 2-fold in WT obese, 
independent of changes in total IRS1 or total Akt (Fig. 6, B-E). Changes in pIRS1 and 
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pAkt were not observed in HZ or KO obese mice; however, insulin-stimulated pIRS1 and 
pAkt were reduced in KO CON relative to WT CON, despite elevated abundance of total 
Akt (Fig. 6, B-E). 
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Discussion 
The most salient findings of this study are that heterozygous knockout of 
adipocyte Pik3r1 reverses obesity induced impairments in glucose tolerance, prevents 
obesity induced systemic and adipocyte insulin resistance and enhances adipocyte insulin 
signaling. This study expands upon previous findings from our laboratory which 
demonstrated that systemic and adipose tissue insulin sensitivity were enhanced in mice 
with whole-body heterozygous knockout (aHZ) of Pik3r1, despite marked obesity (11). 
aHZ mice also had enhanced skeletal muscle and liver insulin sensitivity, so the present 
study has identified an independent role for adipocyte Pik3r1 in regulating adipocyte and 
systemic insulin sensitivity.  
Adipose tissue insulin sensitivity has and continues to be a therapeutic target to 
treat obesity related metabolic diseases (22). The current dogma for which obesity results 
in insulin resistance suggests that obesity is a state of chronic low-grade inflammation, 
which is associated with AT macrophage infiltration, and secondary to this infiltration, 
AT insulin resistance manifests (15). In contrast, however, several studies have shown 
dissociation between AT macrophage and the development of insulin resistance. Lee et 
al. (8) demonstrated that despite knockout of peritoneal macrophage, three days of HFD 
treatment was sufficient to drive insulin resistance; however, the same study revealed that 
inflammation was necessary for obesity induced insulin resistance. Furthermore, findings 
in aHZ mice suggest that it is not obesity, per se, that drives adipose tissue inflammation 
as obese aHZ mice have reduced AT macrophage infiltration, along with enhanced 
insulin sensitivity (11). Although we did not measure AT inflammation in the present 
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study, it is clear from the present study and previous work from our laboratory (11) that 
AT Pik3r1 expression is involved in regulating AT inflammation and insulin sensitivity. 
PI3K functions as a heterodimer, in which the a regulatory subunits (Pik3r1) all 
contain binding sites for the p110a catalytic subunit (2). The regulatory subunits also 
contain an inter-SH2 (iSH2) domain which recognize upstream phosphorylated tyrosine 
residues on insulin receptor substrate-1 (IRS-1) (2). Thus, we hypothesized that adipocyte 
insulin signaling would only be impaired downstream of PI3K in HZ and KO obese mice, 
which aligns with data from aHZ mice (11). Contrary to our hypothesis, we found that 
HZ obese mice have enhanced adipocyte insulin signaling upstream of PI3K (IRS-1 
Y896) relative to WT obese mice, and are protected from an obesity induced decrease 
downstream of PI3K (Akt S473). Unpublished data from our laboratory suggests that HZ 
mice maintain M2-like (anti-inflammatory) macrophage following three days of HFD, 
relative to WT. Furthermore, considering the role of PI3K in regulating inflammation 
(14; 18; 21), we reason that insulin-stimulated phosphorylation of IRS1 is maintained in 
HZ obese mice potentially due to the influence of adipocyte Pik3r1 on adipose tissue 
inflammation in obesity.  
Obesity is strongly associated with insulin resistance, incidence of type 2 diabetes 
mellitus and cardiovascular disease (12). Furthermore, insulin resistance, independent of 
obesity is an independent predictor of type two diabetes mellitus, hypertension, coronary 
heart disease, stroke and some cancers (4). Thus, insulin resistance is a logical therapeutic 
target in obesity. The findings in the present study provide evidence that adipocyte 
Pik3r1 can serve as a therapeutic target to attenuate metabolic diseases associated with 
obesity, independent of changes in body weight and adiposity.  
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Future experiments should assess insulin activation of adipocyte hormone 
sensitive lipase (pHSL Ser660) to assess a critical node in the molecular regulation of 
insulin-stimulated suppression of lipolysis. Data regarding activation of pHSL would 
support our data regarding insulin-stimulated suppression of plasma glycerol.  
Furthermore, considering aHZ mice are protected against obesity induced AT pro-
inflammatory macrophage accumulation, analysis of AT macrophage accumulation is 
warranted in the present study. Taken together, the proposed experiments, in combination 
with previously collected data will allow us to determine the role of adipocyte Pik3r1 in 
regulating both AT insulin sensitivity and AT inflammation. 
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CHAPTER IV 
 
ADIPOSE TISSUE OVEREXPRESSION OF PI3-KINASE P55a IMPROVES 
SYSTEMIC GLUCOSE METABOLISM AND ENHANCES BROWN ADIPOSE 
TISSUE THERMOGENIC ACTIVATION 
Introduction 
 
Class 1a phosphatidylinositol 3-kinases (PI3K) play an essential role in insulin 
stimulation of glucose transport, lipid and protein synthesis, and cell growth and 
differentiation (6) (8); (15). The class 1a PI3 kinases are obligate heterodimers, which 
consist of regulatory subunits (p85, p55, p50) and a catalytic subunit (p110), and exist in 
multiple isoforms (18). The group of regulatory subunits includes p85a, p85b, p55a, 
p55g, p50a. The group of catalytic subunits includes p110a, p110b, and p110d (18). 
The regulatory subunits p85a, p55a, p50a are all encoded by the Pik3r1 gene and 
have identical C-terminal regions that include one proline-rich domain and two SH2 
domains flanking the p110 binding site (5). These individual regulatory subunits, 
however, differ in their N termini. p85a has a large N terminus containing one SH3 
domain, a second proline-rich region, and BCR homology domain; p55a contains a 
unique 34 amino acid extension; and p50a has a shorter 6 amino acid extension (2); (9) 
(10); (11). These regulatory subunits have discrete, but overlapping, tissue distributions, 
such that p85a and p85b are ubiquitously expressed (9), and p50a/p55a are present in 
insulin-responsive tissues including skeletal muscle, liver and brain (2); (10) (11). Mice 
with complete knockout of p85a up-regulate p50a/p55a in skeletal muscle and adipose 
tissue and have enhanced insulin sensitivity, suggesting p50a/p55a are important 
signaling molecules for insulin action (19).  
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While much attention has focused on p85a, little is known about the 
physiological role of p55a or p50a abundance. The structure and function of p55a and 
p50a has not been rigorously investigated (9), although some evidence exists for unique 
signaling capabilities (20). For example, p50a can form a heterodimer with p110 
catalytic subunit that is not sensitive to wortmannin, while p85a and p55a have been 
shown to associate with a wortmannin-sensitive p110 subunit (11). Furthermore, mice 
with a global p55a/p50a deletion have enhanced systemic, skeletal muscle and adipocyte 
insulin sensitivity. Interestingly, however, insulin-stimulated PI3K activity is only 
increased in skeletal muscle suggesting that adipocyte p55a and p50a may have PI3K-
independent roles that influence adipocyte metabolism (7). Obese wild type mice display 
increased abundance of adipose tissue p55a and p50a with a parallel decrease in 
adipocyte insulin sensitivity (13). Obese mice with global heterozygous deletion of 
Pik3r1 do not upregulate adipose tissue p55a and p50a and maintain adipocyte insulin 
sensitivity (13), demonstrating a link between increased adipose tissue p55a/p50a 
abundance and adipocyte insulin resistance. By mimicking conditions in lean mice that 
have been observed in obesity, we can determine whether overexpression of adipocyte 
p55a is sufficient to cause adipocyte insulin resistance, independent of obesity. 
Here, we investigated the hypothesis that adipocyte specific over expression of 
p55a would result in systemic and adipose tissue insulin resistance. To test this, we 
studied systemic glucose tolerance, insulin sensitivity, and adipose tissue insulin 
signaling in male mice with adipocyte specific overexpression of p55a (adipo-p55 OX) 
and WT (Cre negative; p55 flox/flox) littermates. Contrary to our hypothesis, our results 
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demonstrate that adipo-p55 OX mice have enhanced glucose tolerance, adipose tissue 
insulin sensitivity and adipose tissue insulin signaling, relative to WT mice. 
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Methods 
Mouse Model. All experiments were approved by and conducted in accordance 
with the Animal Care Program at the University of Oregon. Studies were conducted in 
male and female mice on a C57BL/6J background. To generate mice with adipose tissue 
specific p55a overexpression, we created p55a knock-in at the ROSA26 locus by 
recombinase-mediated cassette exchange (RMCE).  A p55a recombination cassette was 
made by flanking the cDNA of p55a and a floxed PGK-Puro selection marker followed 
by 4x SV40 polyA STOP signal with FRT and F3.  This cassette together with pCAG-
Flpe were electroporated into ROSA-FNF3-1F1 ES cells (an ES cell line targeted with 
FRT-PGK-neo-F3 at the ROSA26 locus).  The exchange of neo for p55a  at the ROSA26 
locus was facilitated by Flp-recombinase mediated site specific recombination so that the 
recombinants would become G418 sensitive and Puro resistant.  The correct exchange 
was confirmed by PCR.  The 4x SV40 polyA STOP signal along with the selection 
marker PGK-Puro is removed by Cre recombinase.  This puts the p55a cDNA under the 
expression of the endogenous ROSA26 promoter. To generate adipose tissue specific 
overexpression, p55aflox/flox mice were crossed with mice expressing Cre recombinase 
(Cre) under the control of the adipose tissue adiponectin promotor (adipo Cre). After cre 
mediated recombination, the STOP signal was removed, resulting in adipose tissue 
specific p55a overexpression. Herein, Cre negative, p55aflox/flox mice were used as wild 
type (WT) controls for this study. 
Experimental Design. At ten weeks of age, all mice were singly housed and remained on 
standard mouse chow (Lab Diets, Pico Lab, Rodent Diet 20, 5053), housed at 22°C with 
access to nesting material. At eleven weeks of age, mice remained singly housed and were 
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placed in our metabolic monitoring system (Promethion, Sable Systems, Las Vegas, NV.) 
set to 30°C. Mice were euthanized by cervical dislocation following isolfluorane anesthesia 
between 10am and 1pm and tissues (inguinal scWAT, interscapular BAT and perigonadal 
eWAT) were rapidly dissected, snap-frozen in liquid nitrogen and stored at -80°C until 
analysis. 	
Metabolic Monitoring. The metabolic monitoring system is within a thermal 
cabinet, allowing us to monitor mice throughout the experiment. Throughout the 
acclimation period and data collection, the thermal cabinet was set to 30°C, and cages 
were free of nesting material. At twelve weeks of age, we determined total energy 
expenditure during the 12:12-h light-dark cycles (Light Cycle: 6:00-18:00; Dark Cycle: 
18:00-6:00) by monitoring oxygen consumption and carbon dioxide. Food intake and 
energy expenditure were assessed following three full light and dark cycles. The 
measures of O2 consumption and CO2 production in individual chambers were used to 
calculate energy expenditure and the respiratory exchange ratio (RER), which is an index 
of the relative reliance on carbohydrate vs. fat oxidation. Metascreen software (Sable 
Sytems Inc.) was used for data collection and data was processed with ExpeData (Sable 
Systems Inc.) proprietary macros. Energy expenditure (kcals/hour) data were calculated 
relative to bodyweight (kg). Food intake (g/day) data were converted to kcals/day and 
made relative to bodyweight (kg).  
Body Composition.  Body composition (lean tissue, fat and free fluid) was measured 
by time domain (TD)-NMR using the Minispec LF50 mouse NMR (Bruker BioSpin, 
Billerica MA, state) in anaesthetized mice before and after the 1 and 5 day period. 
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Percentages were calculated from body weight measured on a standard scale (Mettlor-
Toledo, Columbus, OH) using the Minispec Software. 
Food Intake and Total Energy Expenditure. Using a metabolic monitoring system 
(Promethion, Sable Systems, Las Vegas, NV), we measured cage behavior (food intake, 
water intake and activity), oxygen, carbon dioxide and water vapor during the 12:12-h 
light-dark cycles (Light Cycle: 6:00- 18:00; Dark Cycle: 18:00-6:00) following one and 
five full light and dark cycles. The metabolic cages were kept inside an environmental 
cabinet allowing temperature control throughout the study. Metascreen software (Sable 
Systems Inc.) was used for data collection and data was processed with ExpeData (Sable 
Systems Inc.) proprietary macros. Energy expenditure (kcals/hour) was calculated relative 
to bodyweight (kg). Food intake (g/day) was converted to kcals/day and made relative to 
bodyweight (kg). 
Oral Glucose Tolerance Test. Glucose tolerance tests were performed in conscious 
mice following the 1d and 5d diet treatment. Mice were fasted for 4 h (6-10 AM) before 
testing to normalize glucose and insulin levels. Tails were nicked with a sterile scissors and 
~2-5 μl of blood was analyzed with a handheld glucometer (Bayer Contour). After the 
fasting glucose measurements, the animals were given 5g dextrose/kg bodyweight by oral 
gavage. Glucose was measured from the tail blood at 10, 20, 30, 45, 60, 75, 90 and 120 
minutes. Glucose area under the curve (AUC) was calculated from baseline glucose values 
using Graphpad Prism 7.0. 
Insulin Tolerance Test. Insulin tolerance tests were performed in conscious mice 
following the 1d and 5d diet treatment. Mice were fasted for 4h (6-10 AM) before testing 
to normalize glucose and insulin levels. Tails were nicked with sterile scissors and ~2-5 μl 
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of blood was analyzed with a handheld glucometer (Bayer Contour). After the fasting 
glucose measurements, the animals received an intraperitoneal (I.P.) injection of 0.25 U 
insulin (Humulin-R, Eli Lilly and Company, Indianapolis, IN)/kg bodyweight. Glucose 
was measured from tail blood again at 10, 20, 30, 40, 50 and 60 minutes. 
Insulin Suppression of Plasma Glycerol. Mice were fasted for 4h (6-10AM). 
Following the 4h fasting period, venous blood was collected from the tail vein through an 
EDTA coated capillary tube, transferred to EDTA coated blood collection tubes and 
stored on ice. Mice were then received an IP injection of 1.0 U insulin (Humulin-R, Eli 
Lilly and Compnay, Indianapolis, IN)/kg bodyweight, and a second blood sample was 
collected 15 minutes following insulin injection. Plasma was separated by spinning tubes 
at 4°C at a speed of 12,000 x g for 15 minutes. Glycerol was assessed by colorimetric 
assay as previously described (13). 
RNA isolation and quantitative real-time PCR. Interscapular BAT was 
homogenized using the Bead Ruptor Elite, Bead Mill Homogenizer (OMNI International, 
Kennesaw, GA) at (5 m/second for 30 seconds x 2) in 100 mg/ 1mL Qiazol (Qiagen, 
Valencia, CA). Total RNA was isolated using a Pure Link RNA Kit (Invitrogen, Eugene, 
OR) according to the manufacturer’s protocol and quantified with a nanodrop 
spectrophotometer. cDNA was synthesized from total RNA using iScript reverse 
transcriptase (BioRad) and gene expression was measured by quantitative real-time PCR 
in CFX384 instrument (BioRad). Gene expression was calculated as the 2-ΔΔCT with target 
genes normalized to beta actin and an internal reference sample (CON diet at 22°C). Mouse 
PCR primers (BioRad) were used for Actb, Ucp1and Prdm16. 
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In vivo insulin signaling. Mice were fasted for 4h (6-10AM), and anesthetized with 
an IP injection of a Ketamine/Xylazine/Acepromazine cocktail. Once mice were non-
responsive, the left perigonadal eWAT depot was removed and immediately flash frozen, 
which served as basal conditions. Insulin (10 U/kg) was then injected into the inferior vena 
cava and the contralateral eWAT depot was removed 5 minutes following the insulin 
injection and immediately flash frozen, which served as insulin stimulated conditions. 
Immunoblotting. eWAT, BAT, liver and skeletal muscle (gastrocnemius) samples 
were homogenized using the Bead Ruptor Elite, Bead Mill Homogenizer (OMNI 
International, Kennesaw, GA) at (5 m/second for 30 seconds x 2) in (20mM Tris-HCl pH 
7.4, 150mM NaCl, 1% Igepal/NP-40, 20mM NaF, 2mM EDTA pH 8.0, 2.5mM NaPP, 
20mM β-glycerophosphate, 10% glycerol with added protease inhibitors (1mg/mL 
Aprotinin, 1mg/mL Leupeptin, 1mg/mL Pepstatin, 6mg/mL Pefabloc SC, Phosphatase 
Inhibitor Cocktail 2 and 3 (Sigma Aldrich, San Jose, CA); eWAT and BAT: 100 mg 
tissue/300µL of Homogenization Buffer; Liver: 100 mg tissue/500µL of Homogenization 
Buffer; gastrocnemius: 100 mg tissue/200µL of Homogenization Buffer). Samples were 
solubilized at 4°C for 1 hour with rotation and spun at 4°C at a speed of 12,000 x g for 
15min. Protein abundance was measured by bicinchoninic acid (BCA) assay (Thermo 
Fisher Scientific, Eugene, OR). Target proteins were measured in tissue homogenates (1 
mg/mL) by capillary electrophoresis using a Wes instrument (Protein Simple, Biotechne) 
with N-SH2 PI3-Kinase (1:100, Millipore Sigma ABS233), pIRS1 Y896 (1:100, Abcam 
ab46800); 1:100 total IRS1 (1:100, Cell Signaling 2382); pAkt S473 (1:100, Cell Signaling 
9271); pan Akt (1:100, Cell Signaling 4691); GAPDH (1:1K, Santa Cruz Biotechnology 
25778); PRDM16 (1:25, Thermo Fisher A5-20872. Data was quantitated using Compass 
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Software (Protein Simple, Biotechne) with target proteins expressed relative to the loading 
control.  
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Results 
Tissue abundance of p55a. Adipo-p55OX mice do not have greater p55a 
abundance is eWAT (Fig. 2A), relative to WT mice; however, p85a was decreased by 35%, 
and there was no difference in p50a (Fig. 2B). BAT p55a abundance was increased 4.5-
fold (Fig. 2C), while no difference in p85a or p50a were detected. No differences in p85a 
(data not shown), p55a or p50a (data not shown) were detected in gastrocnemius (p50a 
WT: 0.15±0.03 v. OX: 0.16±0.04; p85a WT: 0.67±0.05 vs. OX:0.51±0.13; Fig. 2D) and 
liver (p50a WT: 0.71±0.13 vs. OX: 0.69±0.13; p85a WT: 0.91±0.13 vs. OX: 0.95±0.09; 
Fig. 2E) from adipo-p55 OX and WT mice.  
Adipocyte OX of p55a influences perigonadal eWAT mass and interscapular BAT 
mass. No difference in body weight was observed between adipo-p55 OX and WT mice 
(Fig. 3A). No difference was observed in percent fat mass (Fig. 3B), percent lean mass 
(data not shown: WT: 76±0.3 vs. OX:76±0.3) or inguinal scWAT mass (Fig. 3C) between 
adipo-p55 OX and WT mice. Adipo-p55 OX mice had lower perigonadal eWAT mass (Fig. 
3D) and greater interscapular BAT mass (Fig. 3E), relative to WT mice.  
Adipocyte OX of p55a influences kilocalorie intake, substrate oxidation and energy 
expenditure. Kilocalorie intake was greater during the dark cycle, independent of group. 
No difference in kilocalorie intake was observed during the light cycle, however; adipo-
p55 OX mice consumed 25% more kilocalories than WT during the darky cycle (Fig. 4A). 
RER was greater during the dark cycle, independent of group. RER was greater in adipo-
p55OX relative to WT mice during the light (0.79 vs. 0.74) and dark (0.83 vs. 0.77) cycles 
(Fig. 4B). No difference in activity between adipo-p55OX and WT mice was detected 
during the light cycle; however, adipo-p55OX mice recorded less activity during the dark 
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cycle relative to WT mice (Fig. 4C). Energy expenditure was greater during the dark cycle 
independent of group. Adipo-p55OX mice had greater energy expenditure, relative to WT 
mice, during the light and dark cycles (Fig. 4D). 
Adipocyte OX of p55a enhances glucose tolerance but not insulin sensitivity. 
Glucose tolerance was enhanced in adipo-p55OX mice relative to WT, demonstrating 
decreased blood glucose concentrations at 20, 30, 45, 60, 75 and 90 minutes throughout a 
2h oral glucose tolerance test (Fig. 5A). Glucose AUC, quantified from individual oral 
glucose tolerance tests, was reduced in adipo-p55OX mice (Fig. 5B) relative to WT. No 
difference in insulin tolerance was detected between WT and OX mice (Fig. 5C). No 
difference in insulin-stimulated suppression of plasma glycerol was detected between WT 
and OX mice (Fig. 5D). 
Adipocyte OX of p55a do not have impaired adipose tissue insulin signaling. No 
differences in maximal insulin-stimulated phosphorylated IRS1(Y896) (Fig. 6A), 
phosphorylated AKT(S473) (Fig. 6B), total IRS1 (Fig. 6C) or total AKT (Fig. 6D) were 
detected between WT and adipo-p55OX mice. 
Adipocyte OX of p55a increases markers of adipose tissue thermogenesis in BAT. 
BAT Ucp1 gene expression was increased in adipo-p55OX mice (Fig. 7A). BAT UCP1 
protein abundance increased in adipo-p55OX mice (Fig. 7B).  BAT Prdm16 gene 
expression was increased in adipo-p55OX mice (Fig. 7C). BAT PRDM16 protein 
abundance was increased in adipo-p55OX mice (Fig. 7D). 
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Discussion 
The most salient findings in the present study are that adipo-p55aOX mice have 
decreased eWAT p85a abundance, enhanced glucose tolerance, which was associated 
with increased BAT mass, energy expenditure, lipid utilization and markers of adipose 
tissue thermogenesis in BAT. This is the first study to assess the role of adipocyte 
specific p55a OX in vivo and demonstrates a novel role of BAT p55a in the regulation of 
adipose tissue thermogenesis and glucose metabolism. 
Given the inverse association of adipose tissue p55/p50a abundance with 
systemic and adipocyte insulin sensitivity in lean (7) and obese (13) mice, we 
investigated whether overexpression of adipocyte p55a is sufficient to decrease glucose 
tolerance and adipose tissue insulin sensitivity. Contrary to our hypothesis, we found that 
adipo-p55 OX mice have enhanced glucose tolerance. Furthermore, enhanced glucose 
tolerance was associated with elevated BAT mass, lipid utilization and energy 
expenditure. Changes in glucose tolerance occurred independent of differences in 
perigonadal eWAT insulin signaling or insulin sensitivity, but were associated with 
increased BAT UCP1 and PRDM16 gene and protein expression. PRDM16 is necessary 
for increased uncoupling in adipose tissue (17), thus PRDM16 serves as a crucial target 
in adipose tissue thermogenic programming.  
Increased PI3K p85a is a potent negative regulator of insulin sensitivity (3) due to 
the resulting decrease in PI3K enzyme activity. Furthermore, PI3K p110a catalytic 
subunit deletion has opposite effects on insulin sensitivity, compared to p85a regulatory 
subunit deletion (4). Interestingly, mice with adipose tissue specific (WAT and BAT) 
deletion of p110a have decreased insulin sensitivity and energy expenditure (14). 
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Considering eWAT p85a abundance was decreased and BAT p55a was increased in the 
present study, we reason that abundance of these proteins may be influencing BAT 
mitochondrial oxygen consumption, similar to previous reports (14).  
Mammalian target of rapamycin complex 2 (mTORC2), a protein recruited to 
lipid membrane bound phosphatidylinositol 3,4,5-triphosphate (PIP3), following PI3K 
activation of phosphatidylinositol 4,5-biphosphate (PIP2) to PIP3 (12), is necessary for 
cold-induced increases in adipose tissue thermogenesis and BAT glucose uptake (1). 
Furthermore, phosphorylated Akt2(S474), a downstream target of PI3K, is necessary for 
cold-induced increases in BAT uncoupling and fatty acid oxidation (16), through a 
ChREBP (Carbohydrate-repsonsive element-binding protein) mechanism.  
Taken together, we have identified and begun to characterize a novel role of 
adipose tissue p55a in regulating glucose homeostasis and BAT thermogenesis. This 
study adds to the body the body of literature that suggests, rather than a single PI3K 
subunit alone, it is the molecular balance of PI3K subunits that plays a more critical role 
in regulating glucose homeostasis. Furthermore, interventions that enhance energy 
expenditure and glucose tolerance may be favorable for treating the metabolic diseases 
associated with obesity. Future studies are necessary to fully characterize the mechanism 
by which p55a regulates BAT thermogenesis and energy expenditure. Considering the 
differences in energy expenditure, it may be determined that adipo-p55OX mice are 
protected against diet induced obesity and/or obesity induced insulin resistance.  
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CHAPTER V 
 
SHORT-TERM THERMONEUTRAL HOUSING ALTERS GLUCOSE 
METABOLISM AND MARKERS OF ADIPOSE TISSUE BROWNING IN 
RESPONSE TO HIGH FAT DIET IN LEAN MICE 
Clayton ZS and McCurdy CE. Short-term thermonetural housing alters glucose 
metabolism and markers of adipose tissue browning in response to a high fat diet in lean 
mice. American Journal of Physiology Regulatory, Integrative and Comparative 
Physiology 23:doi 10.1152. 2018. 
ZSC performed experiments; ZSC and CEM analyzed data; ZSC and CEM interpreted 
results from experiments; ZSC and CEM drafted manuscript; ZSC and CEM revised 
manuscript; ZSC and CEM approved final version of manuscript; ZSC and CEM 
conception and design of research; ZSC and CEM prepared figures. 
 
Introduction 
Obesity-induced insulin resistance is thought to occur secondary to the release of 
pro-inflammatory cytokines and chemokines, which may be secreted as an adaptive 
response to maintain adipose tissue function in the presence of expanding or hypoxic 
adipocytes  (34). Adipose tissue-derived cytokines and chemokines have been shown to 
regulate insulin action in an autocrine, paracrine and endocrine manner (31) . However, the 
mechanism(s) that regulate and initiate the inflammatory response in obesity are not clearly 
understood. High fat diet induced glucose intolerance and insulin resistance have been 
observed in both lean rodents (23, 24, 27, 35 47) and humans (7) in as little as three days 
of high fat feeding. Interestingly, Lee and colleagues demonstrated in mice that 
inflammation is not necessary for the three day HFD- induced glucose intolerance and 
insulin resistance (27), despite a marked increase in pro-inflammatory gene expression in 
white adipose tissue (WAT). Recent studies have identified a relationship between housing 
temperature and inflammatory response (17); the mice in the study by Lee et al were 
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housed well below the murine thermoneutral zone (29-34°C) (27), which may confound 
these results. For example, Tian and colleagues demonstrated that long-term (9-10 weeks) 
thermoneutral housing of mice accelerates perivascular white adipose tissue (pvWAT) 
inflammation in response to HFD (42), and Giles and colleagues have shown that 
thermoneutral housing as compared to conventional housing exacerbates 
lipopolysaccharide induced inflammation (15). 
In most laboratories, mice are housed at room temperature, between 20-26°C, 
which is recommended within the Guide for the Care and Use of Laboratory Animals (1). 
Mice housed at routine vivarium temperatures have been shown to have less adipose tissue 
inflammation relative to mice housed at thermoneutral temperatures, and have also been 
shown to have greater energy intake and expenditure (12). Together, these results may 
influence net energy balance and potentially lead to unpredictable outcomes in metabolic 
data. Considering the laboratory mouse is used as a preferred model system for the study 
of many metabolic diseases, due to the relative ease of creating genetic perturbations, it is 
imperative to understand the differences between mouse and human thermal physiology, 
to ensure the applicability of preclinical findings. Housing mice below their thermoneutral 
zone has been referred to as a subthermoneutral  stress (17), which is not common in human 
dwellings of daily life.  
Chronic subthermoneutral stress has been shown to promote non-shivering 
thermogenesis, which is achieved through mitochondria rich brown adipose tissue (BAT) 
(12).  BAT contains uncoupling protein-1 (UCP-1), which serves to mediate heat 
generation by uncoupling of oxidative phosphorylation from ATP synthesis (18). Chronic 
cold exposure not only influences inflammation and energetics, but has been shown to 
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upregulate BAT mass, Ucp1 gene expression in BAT, as well as induce “browning” of 
white adipose tissue (WAT), through increased Ucp1 gene expression and an increase in 
multilocular cells within WAT (30). BAT activity has been estimated to account for 2.7%- 
5% of basal metabolic rate in humans, which could cumulatively promote more than 4 kg 
of fat loss per year (45,  46).  Furthermore, increased BAT mass has been shown to regulate 
glucose homeostasis and improve insulin sensitivity in a mass dependent manner (37).  
Currently, most studies comparing behavioral, metabolic and inflammatory 
responses to varying ambient temperatures have been long-term (> 8 weeks). An acute 
response to changes in housing temperature on metabolic variables in the laboratory mouse 
has not been examined. Therefore, the purpose of this study was to investigate the effect 
of short-term thermoneutral housing (30°C) compared to standard vivarium housing 
temperature (22°C) on glucose tolerance, metabolism and behavior (food intake, activity) 
in response to HFD. 
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Methods 
Experimental Design. All experiments were approved by Institutional Animal Care 
and Use Committee at the University of Oregon. Mice with a mixed B6/129S background 
and homozygous for loxP sites flanking exon 8 of the Pik3r1 gene (Pik3r1tm1Lca/J; Jackson 
Laboratory, #012871) were used in these studies. Mice with the targeted allele compared 
to wild type show no difference p85α abundance in the absence of recombinant cre (Fig. 1 
A,B) (2, 28)) and were used in thermoneutral studies to complement ongoing work in this 
mouse line. All mice were housed at standard vivarium temperature (TS; 22°C) with a 
12:12-h light-dark cycles (Light Cycle: 6:00- 18:00; Dark Cycle: 18:00-6:00) and fed chow 
diet with 13% fat (Picolab Rodent Diet 20; LabDiet) until 10 weeks of age. At ten weeks 
of age, male mice were singly housed in standard-sized cages and placed within an 
environmental cabinet set at Ts and fed a control diet (CON: 10% Calories from fat; 
Research Diets, D1245OH) for one week. The 12h light /dark cycle remained the same 
throughout the study.  After the cage acclimation period, mice remained on CON diet but 
were randomly assigned to murine thermoneutral temperature (TN; 30°C) or remained at 
TS for 1 week. At 12 weeks of age, mice either remained on CON diet or were switched to 
a HFD (45% Calories from fat; Research Diets, D12451) for 1d (1 full light:dark cycle) or 
5d (5 full light:dark cycles). Both the CON and HF diets were matched for sucrose (17%). 
At the end of the diet period, mice were euthanized by cervical dislocation following 
isolfluorane anesthesia between 10am and 1pm and tissues (inguinal scWAT, interscapular 
BAT and perigonadal eWAT) were rapidly dissected, snap-frozen in liquid nitrogen and 
stored at -80°C until analysis. 
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Body Composition.  Body composition (lean tissue, fat and free fluid) was measured 
by time domain (TD)-NMR using the Minispec LF50 mouse NMR (Bruker BioSpin, 
Billerica MA, state) in anaesthetized mice before and after the 1 and 5 day period. 
Percentages were calculated from body weight measured on a standard scale (Mettlor-
Toledo, Columbus, OH) using the Minispec Software.  
Food Intake and Total Energy Expenditure. Using a metabolic monitoring system 
(Promethion, Sable Systems, Las Vegas, NV), we measured cage behavior (food intake, 
water intake and activity), oxygen, carbon dioxide and water vapor during the 12:12-h 
light-dark cycles (Light Cycle: 6:00- 18:00; Dark Cycle: 18:00-6:00) following one and 
five full light and dark cycles. The metabolic cages were kept inside an environmental 
cabinet allowing temperature control throughout the study. Metascreen software (Sable 
Systems Inc.) was used for data collection and data was processed with ExpeData (Sable 
Systems Inc.) proprietary macros. Energy expenditure (kcals/hour) was calculated relative 
to bodyweight (kg). Food intake (g/day) was converted to kcals/day and made relative to 
bodyweight (kg). 
Oral Glucose Tolerance Test. Glucose tolerance tests were performed in conscious 
mice following the 1d and 5d diet treatment. Mice were fasted for 4 h (6-10 AM) before 
testing to normalize glucose and insulin levels. Tails were nicked with a sterile scissors and 
~2-5 μl of blood was analyzed with a handheld glucometer (Bayer Contour). After the 
fasting glucose measurements, the animals were given 5g dextrose/kg bodyweight by oral 
gavage. Glucose was measured from the tail blood at 10, 20, 30, 45, 60, 75, 90 and 120 
minutes. Glucose area under the curve (AUC) was calculated from baseline glucose values 
using Graphpad Prism 7.0. 
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Insulin Tolerance Test. Insulin tolerance tests were performed in conscious mice 
following the 1d and 5d diet treatment. Mice were fasted for 4h (6-10 AM) before testing 
to normalize glucose and insulin levels. Tails were nicked with sterile scissors and ~2-5 μl 
of blood was analyzed with a handheld glucometer (Bayer Contour). After the fasting 
glucose measurements, the animals received an intraperitoneal (I.P.) injection of 0.25 U 
insulin (Humulin-R, Eli Lilly and Company, Indianapolis, IN)/kg bodyweight. Glucose 
was measured from tail blood again at 10, 20, 30, 40, 50 and 60 minutes. 
RNA isolation and quantitative real-time PCR. Inguinal subcutaneous white 
adipose tissue (scWAT), perigonadal epididymal white adipose tissue (eWAT) and 
interscapular BAT were homogenized using the Bead Ruptor Elite, Bead Mill 
Homogenizer (OMNI International, Kennesaw, GA) at (5 m/second for 30 seconds x 2) in 
100 mg/ 1mL Qiazol (Qiagen, Valencia, CA). Total RNA was isolated using a Pure Link 
RNA Kit (Invitrogen, Eugene, OR) according to the manufacturer’s protocol and quantified 
with a nanodrop spectrophotometer. cDNA was synthesized from total RNA using iScript 
reverse transcriptase (BioRad) and gene expression was measured by quantitative real-time 
PCR in CFX384 instrument (BioRad). Gene expression was calculated as the 2-ΔΔCT with 
target genes normalized to beta actin and an internal reference sample (CON diet at 22°C). 
Mouse PCR primers (BioRad) were used for Actb, Ucp1, Prdm16, Cidea, Cox8b, Pgc1a, 
Adipoq, Leptin, Il1b, Il4, Il6, Il10, Il13, Ifng, and Ccl2.  
Immunoblotting. scWAT, eWAT and BAT samples were homogenized with a BDC 
2002 (Compact Digital, Caframo Lab Solutions, Ontario, Canada) at 100mg tissue/ 300µL 
of homogenization buffer (20mM Tris-HCl pH 7.4, 150mM NaCl, 1% Igepal/NP-40, 
20mM NaF, 2mM EDTA pH 8.0, 2.5mM NaPP, 20mM β-glycerophosphate, 10% glycerol 
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with added protease inhibitors (1mg/mL Aprotinin, 1mg/mL Leupeptin, 1mg/mL 
Pepstatin, 6mg/mL Pefabloc SC, Phosphatase Inhibitor Cocktail 2 and 3 (Sigma Aldrich, 
San Jose, CA)). Samples were solubilized at 4°C for 1 hour with rotation and spun at 4°C 
at a speed of 12,000 x g for 15min. Protein abundance was measured by bicinchoninic acid 
(BCA) assay (Thermo Fisher Scientific, Eugene, OR). Target proteins were measured in 
tissue homogenates (1 mg/mL) by capillary electrophoresis using a Wes instrument 
(Protein Simple, Biotechne) with rabbit polyclonal antibodies for PRDM16 (1:25, PA5-
20872; Thermo Fisher Scientific; Eugene, OR), UCP1 (1:50, PA1-24894; Thermo Fisher 
Scientific; Eugene, OR) or PI3-Kinase p85 (1:25, ABS233; EMD Millipore; Burlington, 
MA) and with GAPDH (1:1K, 25778; Santa Cruz Biotechnology; Santa Cruz, CA) as a 
loading control. Data was quantitated using Compass Software (Protein Simple, Biotechne) 
with target proteins expressed relative to the loading control.  
In vivo 3H-2-deoxy-d-glucose uptake. To measure tissue-specific glucose uptake 
after one day of diet treatment, mice were fasted for 4h (6-10 AM), and injected I.P with 2 
g/kg cold glucose spiked with 0.5µCi/g 3H-2-deoxy-d-glucose (Perkin Elmer, Waltham, 
MA). Tissues were harvested 30 minutes after the injection, weighed, and snap frozen in 
liquid nitrogen. Tissues were processed in 1 mL homogenizing buffer with glass on glass 
kontes tubes using a BDC 2002 homogenizer (Caframo, Compact Digital, Ontario, 
Canada). 50 µL of homogenate was counted on a scintillation counter. A BCA assay was 
ran on individual tissue lysates and counts per minute (CPM) were made relative to tissue 
weight.  
Statistical Analysis.  Data were analyzed by a two-way analysis of variance 
(ANOVA) for main effects of diet and temperature except for the oral glucose tolerance 
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test, which used a repeated measures 2-way ANOVA for main effects of group and 
temperature. A Sidak’s multiple comparisons post hoc test was performed when significant 
main effect differences were detect using a p-value of < 0.01. All data are presented as the 
mean ± standard error of the mean (SEM). Statistics were calculated using Graph Pad Prism 
version 7 (Graph Pad Software; La Jolla, CA). No differences were detected between 1 and 
5d CON at each temperature for all physiological measures (data not shown). Herein, 1d 
CON data are reported. 
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Results 
Short-term thermoneutral housing combined with acute HFD increases bodyweight 
and adiposity in male mice. Body weight was increased in male mice housed at 30°C for 8 
days (d) compared to 22°C with CON or HFD; however, these temperature-mediated 
differences in body weight were ameliorated by a longer (5d) HFD exposure (Fig. 1D). 
Short-term TN as compared to Ts housing also altered body composition. Percent fat mass 
increased independent of diet type (CON vs HFD) or duration of HFD (Fig. 1E). The 
percent lean mass was reduced in 30°C vs. 22°C with 1d CON and HFD but similar to body 
weight, temperature-mediated differences in lean mass were absent with 5d HFD. At 22°C, 
5d HFD reduced the percent lean mass as compared to 1d CON and 1d HFD (Fig. 1F). The 
increase in percent fat mass with TN housing is driven, in part, by an increase in scWAT 
(and eWAT mass with 1d CON and 1d HFD (Fig. 1, G-H). eWAT mass was not different 
between Ts and TN housing with 5d HFD (Fig. 1I).  BAT mass was reduced by in CON 
(100±3 mg vs. 85±3 mg), 1d HFD (100±5 mg vs. 77±4 mg) and 5d HFD (120±5 mg vs. 
69±8 mg) with TN housing (Fig. 1G).  
Short-term thermoneutral housing alters the mouse behavior and the metabolic and 
circadian response to HFD.  Mouse feeding behavior was changed by both diet and 
housing temperature. Specifically, TN suppressed food intake on 1d CON diet (118±21 
kcals vs. 57±14 kcals), but not 1 day and 5 day HFD, during the light cycle compared to 
22°C (Fig. 2A).  Additionally, HFD increased light cycle food intake at both temperatures 
and was greater with 5d HFD (22°C: 182±18 kcals vs. 118±21 kcals; 30°C: 160±9 kcals 
vs. 57±14 kcals) compared to 1d CON (Fig. 2A). During the dark cycle, HFD led to a 
stepwise increase in daily food intake (kcals/kg) only at Ts (CON: 223±18 kcals; 1d HFD: 
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274±22 kcals; 5d HFD: 312±18 kcals) and was significantly greater after 5d with HFD 
relative to CON diet (Fig. 2B). No difference in food intake between diet groups was 
observed at 30°C (Fig. 2B). There was a significant interaction of diet and housing 
temperature on measurements of RER in both the light and dark cycle (Fig. 2, C-D). RER 
was higher in mice on the 1d CON diet at 22°C vs. 30°C in both the light (0.92 vs. 0.82) 
and dark (0.92 vs. 0.84) cycle. At Ts housing, RER was lower with HFD as anticipated 
during the light and dark cycle (Fig. 2, C-D).  In contrast, RER was not different between 
mice fed CON vs. HFD at TN housing during the light cycle and the difference in dark cycle 
RER observed at 22°C with HFD was diminished at 30°C (Fig. 2, C-D). There were no 
differences in total activity during the light cycle by diet or temperature (Fig.2, E); 
however, there was a significant interaction of diet and housing temperature on 
measurements of total activity during the dark cycle (Fig. 2F).  At 22°C, HFD (1 and 5d) 
increased dark cycle activity (1d HFD: 112±10; 5d HFD: 120±8 meters (m)) compared to 
CON (70±4 m). In contrast, dark cycle activity was not influenced by diet in mice housed 
at 30°C; activity of mice on CON diet was as great as mice on HFD (CON: 119±8; 1d 
HFD: 103±7; 5d HFD: 124±9 m). There was no additive effect of HFD on activity of mice 
at TN (Fig.2F). Energy expenditure was lower with 30°C vs. 22°C independent of diet 
throughout the circadian cycle (Fig. 2, G-H).  
Thermoneutral housing alters glucose metabolism and insulin sensitivity in 
response to a HFD. Fasting glucose increased with 5d HFD compared to CON and 1d HFD 
within each housing temperature; however, fasting glucose was lower in each diet group at 
30°C housing (Fig. 3A). Glucose tolerance was reduced following 1d and 5d of HFD 
feeding and was only influenced by temperature at the 10min time-point at 22°C following 
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1d HFD (Fig. 3, B-D). There were no differences between all CON groups (data not shown) 
and all HFD groups (data not shown). There was no effect of diet or temperature on glucose 
disposal in response to an insulin bolus after 1d; however, a 5d HFD at 22°C but not 30°C 
significantly decreased insulin sensitivity (Fig. 3, E-F). Examining tissue-specific effects 
of temperature on glucose metabolism, we found that housing temperature shifted the 
distribution of glucose uptake during insulin-stimulated condition such that glucose uptake 
was highest in soleus muscle at 30°C while BAT had the greatest uptake at 22°C in mice 
on CON diet.  With 1d HFD, we found tissue-specific reductions in glucose disposal by 
temperature. Specifically, 1d HFD decreased BAT glucose disposal by 63% at 22°C 
housing but not 30°C (Fig. 3, G-H). In contrast, at 30°C housing but not 22°C, soleus 
glucose disposal was reduced by 54% with 1d HFD feeding (Fig. 3, E-F).  
Thermonetural housing reduces markers of adipose tissue thermogenesis in BAT. 
In addition to the decrease in BAT mass, TN housing also decreased gene expression of key 
regulators of thermogenesis. Specifically, there was a main effect of temperature to 
decrease Ucp1, Prdm16, Cox8b and Pgc1a expression after 8 and 12d at 30°C compared 
to constant 22°C housing (Fig. 4, A-D). For Ucp1 and Pgc1a (Fig. 4, A, D), the decrease in 
expression with 30°C was independent of diet type (CON vs. HFD) and time on diet (1d 
vs. 5d). Prdm16 expression was decreased at 30°C after 1d, independent of diet; however, 
it was only decreased with HFD and not CON diet with longer exposure at 30°C (Fig. 4B) 
suggesting a transient effect of temperature on Prdm16 expression in mice fed a CON diet.  
Cox8b expression was only decreased at 30°C with HFD independent of time on diet (Fig. 
4C). As these are relatively small changes in gene expression, we sought to determine 
whether the differences were sufficient to alter protein abundance. PRDM16 protein 
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abundance was decreased at 30°C following 1d HFD treatment (Fig. 4, E-F), while no 
difference was detected for UCP1 (Fig. 4 E, G). 
Diet and thermoneutral housing reduce some markers of adipose tissue browning 
in inguinal scWAT but not eWAT. In scWAT, there was a main effect of temperature to 
decrease Ucp1, Cox8b and Pgc1a expression with TN compare to TS housing. Specifically, 
Ucp1 expression was decreased at 30°C compared to 22°C independent of diet type (CON 
vs. HFD) and time on diet (1d vs. 5d). Cox8b (Fig. 5B), Pgc1a (Fig. 5D) and Prdm16 (data 
not shown) gene expression was decreased at 30°C compared to 22°C only after longer 
time (12d) in TN conditions independent of diet type. Similar to the changes in Ucp1 
expression, Cidea expression was decreased at 30°C independent of diet type (CON vs. 
HFD) or length of time at TN conditions (8 and 12d); additionally, 5d HFD feeding further 
reduced Cidea expression compared to 5d CON at 30°C (Fig. 5C). Thermoneutral housing 
did not decrease Ucp1, Prdm16, Cidea, Cox8b or Pgc1a gene expression in visceral eWAT 
tissue following 1d or 5d of diet (data not shown).  
Thermal neutral housing augments the effect of high fat diet to reduce anti-
inflammatory gene expression in inguinal scWAT. With 1d of HFD compared CON, there 
was no change in the gene expression of Il4, Il10, and Il13 anti-inflammatory markers at 
either temperature in both scWAT and eWAT depots (Fig. 6, A-F). However, with longer 
diet exposure, there was a significant interaction between diet and temperature to reduce 
the gene expression of these key anti-inflammatory markers in scWAT. Specifically, Il4, 
Il10, and Il13 were reduced with 5d of HFD diet feeding only at 30°C and not at 22°C(Fig. 
6, A, C, D). In contrast, there was no change in the gene expression of Il4, Il10, and Il13 
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with temperature in eWAT following 5d diet treatment (Fig. 6, B, D, F). Il13 expression 
was increased in eWAT with 5d HFD compared to CON at 22°C, but not at 30°C (Fig 6F)  
Thermal neutral housing attenuates the effect of a high fat diet to increase pro-
inflammatory gene expression in eWAT. Overall, expression of some pro-inflammatory 
genes were elevated by short –term HFD in eWAT at TS housing but this effect was lost 
with TN housing. Specifically, there was no effect of diet (1 or 5d) or temperature on Tnfa 
expression in eWAT (Fig. 7A). There was a transient effect of HFD to increase Il1b with 
1d at 22°C, but not at 30°C, that was diminished by longer exposure to HFD in eWAT (Fig. 
7B). Il6 expression increased following 1d and 5d of HFD at 22°C and not 30°C in eWAT 
(Fig. 7C). Lastly, Ccl2 expression was significantly higher at 30°C compared to 22°C with 
longer exposure to TN housing; exposure to 5d HFD in mice at 22°C increased Ccl2 
expression to levels to mice at 30°C in eWAT (Fig. 7D). No differences were detected in 
Tnfa, Il1b, Il6 or Ccl2 gene expression in scWAT with short-term HFD diet or housing 
temperature (data not shown). 
 
 
 
 
 
 
 
 
 
		 66 
Discussion 
The most salient findings of this study are that TN housing altered the metabolic and 
cellular response to acute HFD in key pathways that have been implicated in HFD-induced 
insulin resistance. To our knowledge, this is the first study to assess the effect of TN housing 
on in vivo glucose metabolism, adipose tissue browning and adipose tissue inflammatory 
gene expression after such a brief time domain (8 or 12 days total: 7-day acclimation + 1 
or 5 day diet treatment).  
Short-term TN housing had a significant and rapid impact on the phenotype and 
metabolism of the mice. Specifically, TN housing influenced food intake, activity, EE and 
RER resulting in altered fat accretion, adipose tissue distribution and substrate utilization. 
We found that TN housing decreased food intake during the light cycle relative to mice 
housed at Ts, particularly in mice on the CON diet. This increase in food intake may be 
necessary to support the higher EE measured in TS vs. TN; These observations are in 
agreement with previous reports (10, 17) showing an inverse relationship between housing 
temperature and food intake in chronic conditions. For example, in a 20-week study that 
utilized a similar experimental design, mice housed at 30°C had increased WAT (scWAT 
and eWAT) mass and decreased BAT mass relative to mice housed at 22°C (10). Our data 
shows that these changes in adipose tissue (scWAT, eWAT and BAT) mass in the response 
to housing temperature occur very rapidly with as little as 8d acclimation. We also found 
that RER was higher at 22°C housing relative to 30°C across both the light and dark cycles 
with control diet feeding, which supports previous studies showing higher carbohydrate 
oxidation in mice on a standard chow diet housed at lower temperatures for longer periods 
of time (11, 13, 17). We did not observe temperature differences in RER during HFD 
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feeding likely reflecting the greater influence of the diet composition (i.e. higher fat) on 
metabolism and the overall decrease in glucose tolerance. We also found that BAT glucose 
uptake at 22°C during CON feeding was much higher relative to CON fed mice at 30°C. 
At the cellular level, increased glucose utilization by BAT at 22°C is supported by higher 
gene expression of Ucp1, Pgc1a, Prdm16, and PRDM16 protein abundance, which 
combined promote mitochondrial metabolism that is favorable for heat generation through 
uncoupled respiration (5). Although 1d exposure to 4°C) has shown to be sufficient to 
decrease BAT UCP1 protein abundance relative to 22°C (21), we did not see a difference 
in the present study with 8d acclimation likely due to the large variability in the 
measurement. Taken together, these data demonstrate that short-term thermoneutral 
housing is sufficient to alter energy intake, adipose tissue weight, substrate utilization and 
energy expenditure.  
Fasting glucose is primarily regulated by hepatic glycogen stores (32) and is 
influenced by circulating catecholamines. Subthermoneutral stress increases sympathetic 
nervous system (SNS) activity and increases circulating norepinephrine (10). Although we 
do not have data regarding norepinephrine turnover, we speculate that the increase in 
fasting glucose measured at Ts housing may be due to elevated norepinephrine in response 
to subthermoneutral stress that results in increased hepatic glycogenolysis (19). After five 
days of HFD, we find that fasting glucose increased in mice housed at both 22°C and 30°C, 
but was higher in all conditions (CON and HFD) in mice at 22°C vs. 30°C. Although we 
observed differences by housing temperature in several factors that have been shown to 
influence glucose tolerance (energy expenditure (48), BAT mass (37) and upregulation of 
UCP1 in BAT and scWAT (38), no differences were detected in glucose tolerance between 
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mice housed at 22°C and 30°C . Additionally, we found a similar decrease in glucose 
tolerance with 1d and 5d HFD feeding at both housing temperatures. To our knowledge, 
this is the first rodent study to identify mild glucose intolerance following one day of HFD 
feeding. The magnitude of change in glucose AUC with 5 days of HFD and was not greater 
than at 1 day.  Interestingly, when Cui and colleagues (10) pair fed mice housed at 22°C to 
match the reduced intake of mice at 30°C, mice housed at 22°C displayed improvements 
in glucose tolerance and insulin sensitivity. Thus, we may have seen temperature based 
differences in glucose tolerance across, if we had implemented pair-feeding. 
Although systemic glucose tolerance was similar by temperature, we found tissue-
specific differences in glucose clearance indicating that the cellular mechanisms that lead 
to reduced glucose tolerance with HFD acutely are different depending on housing 
temperature. Specifically, HFD-feeding reduced insulin-mediated BAT glucose uptake in 
mice at 22°C but reduced soleus muscle glucose uptake in mice at 30°C. The increase in 
BAT glucose uptake at Ts likely reflects the greater energy demand of BAT in mice housed 
at 22°C vs. 30°C, which is reflected by the decrease in BAT mass and EE in mice housed 
at TN. These findings have significant implications for studies examining mechanisms that 
initiate insulin resistance in obesity as it suggests that mice living under conditions of 
chronic subthermoneutral stress respond differently to HFD challenges than those housed 
in TN conditions. 
Expansion of scWAT, even in the face of obesity, has been suggested to promote 
insulin sensitivity in both rodents and humans (25, 26, 29, 33, 36, 40). Implantation of 
scWAT, but not visceral WAT, into the abdominal cavity of mice improves whole body 
metabolism (20, 44). In further support that scWAT and eWAT depots are cell 
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autonomous, Stanford and colleagues (38) demonstrated that transplantation of scWAT, 
but not eWAT, from exercise trained mice, into the visceral or subcutaneous cavity of 
sedentary and HFD fed mice, significantly improved glucose tolerance and insulin 
sensitivity in recipient mice. The same study also observed an exercise induced increase in 
scWAT Ucp1 and Prdm16 expression, which was not seen in eWAT (38). Moreover, 
inguinal scWAT has been shown to be more susceptible to browning than eWAT (3, 6, 8, 
9, 18). These data agree with our findings that scWAT responds more rapidly than eWAT 
to subthermoneutral stress by increasing markers of browning (Ucp1, Cox8b, Cidea, 
Pgc1a). An inverse relationship between periventricular WAT browning and inflammation 
at 30°C housing was recently shown by Tian and colleagues (43). The study found that 
although inflammation augmented the development of atherosclerosis, it did not influence 
insulin resistance, relative to 22°C. Thermoneutral housing has also been shown to 
exacerbate nonalcoholic fatty liver disease and the response to pro-inflammatory stimuli 
(16, 39) by influencing Toll-Like Receptor 4 (TLR4) responsiveness (16). Knockout of 
TLR4 in adipose tissue has been shown to protect against whole body insulin resistance 
following an acute lipid challenge (41); thus, a connection exists between housing 
temperature, inflammation and whole body glucose metabolism. We also observed subtle 
differences in some inflammatory gene markers following one and more so five day HFD 
feeding that was depot and temperature dependent. Specifically, there was a decrease in 
anti-inflammatory gene expression (Il4, Il10 and Il13) in scWAT only in mice housed at 
30°C after 5d HFD with no increase in pro-inflammatory gene expression. Together, these 
data suggests that a reduction in the anti-inflammatory cytokines in scWAT proceeds or 
initiates the shift to a pro-inflammatory state that is typically associated with obesity. In 
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eWAT, there were again subtle increases in some pro-inflammatory markers (Il1b, Il6 and 
Ccl2) with HFD but only in mice housed at 22°C and not 30°C. The lack of an increase in 
eWAT inflammatory markers in mice housed at 30°C may be attributed to the overall 
greater eWAT and scWAT mass and perhaps greater potential for expansion. WAT 
expansion has been shown to reduced adipose tissue inflammation in obesity (22).  
An increase in BAT mass has been proposed to be a protective mechanism against 
subthermoneutral stress, due to the capacity of BAT to generate heat through uncoupled 
respiration, via UCP1 (5). In a mass dependent manner, BAT has also been associated with 
an increase in energy expenditure and improvements in insulin sensitivity (38). In contrast, 
loss of UCP1 exacerbates HFD induced impairments in glucose metabolism (49) and 
results in obesity even in chow fed rodents (14). To our knowledge, we are the first to 
identify that changes in energy expenditure, BAT mass and downregulation of BAT 
browning genes occurs as rapidly as eight days of TN housing. BAT has also been proposed 
to be a site of diet induced thermogenesis (reviewed in (4)), as a potential protective 
mechanism to enhance energy expenditure in the face of long-term abundant energy intake. 
Here, we observed reduced BAT Ucp1 expression, decreased EE and increased adiposity 
in mice after short-term housing at 30°C relative to 22°C that was associated with greater 
insulin resistance when challenged with a 5d HFD in agreement with previous findings 
conducted over longer time course.  
Herein, we have provided a detailed analysis of the acute metabolic and behavioral 
responses of mice housed at standard vivarium (22°C) and thermoneutral (30°C) 
temperatures, while consuming a HFD (45% Calories from fat) or CON (10% Calories 
from fat diet). We found that one day of HFD was sufficient to impair glucose tolerance 
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despite no evidence of a consistent parallel increase in immune response. Although housing 
temperature did not influence HFD induced glucose tolerance, the tissue-specific responses 
resulting in reduced glucose disposal were altered by housing temperature. Furthermore, 
short-term (8-12 days) thermoneutral housing decreases energy expenditure, BAT mass, 
fasting blood glucose and scWAT/BAT “browning” genes and scWAT anti-inflammatory 
genes. Considering the aforementioned variables have been implicated in mechanisms that 
initiate insulin resistance in obesity, it is important that housing conditions that alter the 
physiology of the model system be considered in interpretation of metabolic data. 
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CONCLUSION 
 
Focus of this Discussion 
This discussion will 1) summarize the key findings of each study, 2) describe how the 
findings advance the current understanding of how adipose tissue Pik3r1 mediates 
changes in insulin sensitivity, 3) identify several new questions raised by the results in 
this dissertation, and 4) propose a follow up experiment to address one of these questions. 
Summary of Key Findings 
 Results from this dissertation provide a number of novel insights into the role of 
adipose tissue Pik3r1 in regulating glucose homeostasis, insulin sensitivity and 
thermogenic programming of adipose tissue. Previous research from our laboratory and 
others established a need to investigate the effect of Pik3r1 in regulating glucose 
homoestasis and insulin sensitivity, specifically in adipose tissue. Accordingly, the 
studies in this dissertation focused on understanding the role of Pik3r1 in regulating 
glucose tolerance following acute and long term HFD exposure. As imperative as it is to 
understand how the in vivo systems functions without a particular protein, it is also 
necessary to understand if there is a gain of function mechanism if the protein were to be 
over expressed; thus, we aimed to assess the role of adipose tissue p55a OX in regulating 
glucose homeostasis, insulin sensitivity and adipose tissue thermogenesis. A summary of 
the key findings is provided below. 
Study 1. Heterozygous Knockout of Adipocyte Pik3r1 Protects Against Acute HFD 
Induced Glucose Intolerance and Induced Insulin Resistance 
- In male cre negative pik3r1flox/flox  (WT) mice, eWAT p85a abundance was 
increased 7.5-fold following three days of HFD exposure	
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- Increased eWAT p85a abundance was associated with decreased glucose 
tolerance and insulin sensitivity in WT mice	
- Heterozygous knockout, but not homozygous knockout, of adipocyte Pik3r1 
protected against acute HFD induced glucose intolerance and insulin resistance, 
despite increased body weight and adiposity, relative to WT mice. 	
- Homozygous knockout of adipocyte Pik3r1 resulted in exacerbated levels of 
glucose intolerance, relative to WT mice, insulin resistance and decreased energy 
expenditure	
Study 2. Inducible heterozygous knockout of adipocyte Pik3r1 reverses obesity 
induced glucose intolerance and enhances adipocyte insulin sensitivity 
- Heterozygous knockout, but not homozygous KO, of adipocyte Pik3r1 reversed 
obesity induced glucose intolerance 
- Heterozygous knockout, but not homozygous KO, of adipocyte Pik3r1 protected 
mice from obesity induced impairments in systemic and adipocyte insulin 
resistance 
Study 3. Adipocyte specific overexpression of p55a enhances glucose tolerance, 
energy expenditure and markers of thermogenesis in brown adipose tissue 
- Male mice with adipocyte specific overexpression of p55a enhanced glucose 
tolerance independent of body weight and adiposity, relative to male WT 
(p55flox/flox) mice 
- Male mice with adipocyte specific overexpression of p55a had increased BAT 
mass and enhanced energy expenditure, relative to male WT (p55flox/flox) mice 
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- Male mice with adipocyte specific overexpression of p55a had increased markers 
(gene and protein levels of UCP1 and PRDM16) of thermogenic programming in 
BAT 
Study 4. Short-term thermoneutral housing alters glucose metabolism and markers 
of adipose tissue browning in response to a high fat diet in lean mice 
- Standard vivarium temperature resulted in decreased body weight, percent fat 
mass, inguinal subcutaneous WAT mass, perigonadal eWAT mass in 1d CON, 1d 
HFD and 5d HFD treated WT mice 
- Standard vivarium temperature resulted in increased BAT mass and energy 
expenditure, independent of diet condition in WT mice 
- One day of HFD was sufficient to decrease glucose tolerance, independent of 
housing temperature, and the observed phenotype was not made worse by five 
days of HFD 
- BAT was the preferential tissue for glucose disposal under standard vivarium 
housing conditions, while skeletal muscle was the preferential tissue for glucose 
disposal under thermoneutral conditions 
- Short-term (8 days) thermoneutral housing was sufficient to decrease markers of 
adipose tissue thermogenesis in BAT and inguinal subcutaneous white adipose 
tissue 
- Thermoneutral housing increased proinflammatory gene expression in inguinal 
epididymal white adipose tissue following one day of HFD, relative to mice 
housed at standard vivarium temperature 
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How These Studies Fill Gaps in Current Understanding 
             The studies in this dissertation were designed to fill three main gaps in the 
understanding of how adipose tissue Pik3r1 influences insulin sensitivity and glucose 
homeostasis. The major goal of study 1 was to evaluate the role of HZ knockout of 
adipocyte Pik3r1 in regulating acute HFD induced impairments in glucose intolerance 
and insulin sensitivity. Lee et al. (8) recently demonstrated that three days of HFD was 
sufficient to drive glucose intolerance independent of changes in body weight and 
adiposity. Furthermore, our lab previously showed that obese mice with global HZ 
deletion of Pik3r1 (aHZ)  maintain adipose tissue PI3K activity, as well as adipocyte and 
systemic insulin sensitivity (9). Considering obesity is a progressive disease, and its 
associated comorbidities actually arise prior to a significant gain in body weight or 
adiposity (3), it was crucial to determine the role of adipose tissue Pik3r1 in regulating 
the onset of glucose intolerance and insulin resistance. Study 1 established that increased 
eWAT p85a abundance occurs rapidly and is associated with decreased glucose tolerance 
and insulin sensitivity. Furthermore, by reducing Pik3r1 expression prior to the onset of 
acute HFD treatment, mice maintain glucose tolerance and insulin sensitivity. 
 The major goal of study 2 was to investigate whether HZ knockout of adipocyte 
Pik3r1 would reverse glucose intolerance following the development of obesity. 
Considering previous findings from our lab (9) demonstrate that aHZ mice are not 
resistant to obesity and protected against obesity induced impairments in adipocyte and 
systemic insulin sensitivity, it was crucial to determine whether HZ knockout of 
adipocyte Pik3r1 following the development of obesity would reduce obesity induced 
impairments in glucose tolerance. This study demonstrates that the targeting the 
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metabolic diseases associated with obesity may be of greater importance to overall health 
than weight loss alone. Furthermore, study 2 demonstrates that adipocyte HZ knockout 
protects against obesity induced adipocyte and systemic insulin resistance, as well as 
insulin signaling upstream (p-IRS1 Y896) and downstream (p-AKT Ser473) of PI3K.  
 The major goal of study 3 was to determine the specific role of p55a OX, in vivo, 
on glucose metabolism and insulin sensitivity. To date, p55a OX has only been studied 
in cell culture systems, which is undoubtedly informative for establishing mechanism, but 
lacks translational potential for future clinical interventions. aHZ obese mice were 
protected from an obesity induced increase in eWAT p55a abundance (9), which was 
associated with enhanced adipocyte and systemic insulin sensitivity. Furthermore, global 
knockout of p50a/p55a enhanced adipocyte and systemic insulin sensitivity (5), thus we 
hypothesized that independent of diet, mice with adipocyte specific p55a OX (adipo-
p55OX) would have decreased glucose tolerance and insulin sensitivity. Contrary to our 
hypothesis, we found that adipo-p55OX mice had a two-fold improvement in glucose 
tolerance, relative to p55flox/flox WT controls, which was associated with increased BAT 
mass and energy expenditure. In order to help explain the differences observed in energy 
expenditure, we found that adipo-p55OX mice had increased Ucp1 and Prdm16 (markers 
of thermogenesis) gene expression as well as protein abundance. This study has identified 
a novel role for adipose tissue p55a in regulating glucose homeostasis and adipose tissue 
browning. 
 The major goal of study 4 was to determine the effect standard vivarium housing 
conditions had on glucose metabolism, energy expenditure and adipose tissue browning. 
Considering mouse thermoneutral zone is 30°C and standard vivarium temperature (22-
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23°C) is considered a thermal stress for mice (7), it was imperative to determine whether 
our primary outcome measures were influenced by housing conditions. To date, no 
studies have assessed the short-term effect of thermoneutral housing relative to standard 
vivarium temperature on glucose homeostasis, insulin sensitivity and adipose tissue 
browning. Here, we provide evidence that acute (one and five day) HFD induced glucose 
intolerance is not influenced by housing temperature; however; we did observe a 
divergence in site of glucose disposal, suggesting BAT is the primary site for glucose 
disposal at standard vivarium conditions while the soleus is the primary site for glucose 
disposal under thermoneutral conditions. Furthermore, we observed that eight days of 
thermoneutral housing was sufficient to decrease markers of adipose tissue thermogenesis 
in BAT and scWAT, relative to standard vivarium conditions, which agrees with similar 
findings in long-term thermoneutral exposure (6). Considering we are conducting mouse 
studies to ultimately improve human health, and humans do not typically live in thermal 
stressed conditions, it is imperative we are not biasing our findings by housing mice at 
inappropriate temperatures. 
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Future Experiments 
 To follow up on study 1, it is necessary to determine the immune-phenotype of 
the adipose tissue from mice with HZ knockout of adipocyte Pik3r1. Considering aHZ 
mice are protected from obesity induced AT macrophage infiltration (9), it is necessary to 
determine whether Pik3r1 also influences immune cell abundance, immune cell 
chemotaxis and cytokine production. The current logic behind obesity induced insulin 
resistance is that inflammation is the primary driver of the insulin resistant phenotype; 
however, in the present study, WT mice had impaired glucose tolerance and insulin 
sensitivity following three days of HFD treatment independent of changes in body weight 
or adiposity.  
 To follow up on study 2, it is also necessary to determine the immune-phenotype 
of the adipose tissue from mice with HZ knockout of adipocyte Pik3r1. Findings from 
immune-phenotyping experiments in these mice would build on previous findings from 
aHZ mice (9), where the primary question was whether the adipocyte phenotype 
influenced the immune-phenotype. By using inducible HZ knockout of adipocyte Pik3r1 
following the development of obesity, we will able to determine whether the immune-
phenotype of adipose tissue influences the adipocyte phenotype. 
 To follow up on study 3, it would be informative to perform hyperinsulinemic-
euglycemic clamps on these mice, to determine how adipocyte specific OX of p55a 
influences other tissues (i.e. liver and skeletal muscle) responsible for maintaining 
glucose homeostasis (2). Considering the adipo-p55OX mouse is a novel mouse model, it 
is important to further pursue the mechanism as to how adipo-p55OX improves BAT 
thermogenesis, and whether these differences actually result in increased heat generation. 
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As described in figure 1, we propose that BAT PI3K plays a direct role in regulating 
BAT thermogenesis and increasing energy expenditure. Furthermore, it would be 
informative to determine if adipo-p55OX mice also have increased browning of WAT. 
Initially, we should determine whether adipo-p55OX mice have morphological changes 
(increased abundance of multilocular, brown adipocytes) in WAT. A third experiment to 
initially conduct to follow up on the findings in this dissertation is to determine whether 
adipo-p55OX mice are protected from obesity induced insulin resistance. 
 To follow up on study 4, we should assess morphological changes in scWAT to 
determine whether there is a unilocular to multilocular cell shift, which would be 
indicative of WAT browning. Furthermore, it would be important to determine whether a 
more long-term thermoneutural exposure, prior to the onset of HFD, would influence the 
metabolic response to HFD.  
 
Conclusion 
In conclusion, this dissertation has provided novel insights into the role of 
adipocyte Pik3r1 in regulating acute and long term HFD induced insulin resistance. 
Furthermore, this dissertation has characterized glucose metabolic profile of a novel 
mouse model of adipocyte specific OX p55a. Moreover, studies in adipo-p55OX mice 
reveal a novel role for BAT p55a in regulating BAT thermogenesis and energy 
expenditure. Lastly, this dissertation provides evidence that short-term housing of mice 
within their thermoneutral zone has a rapid impact on adipose tissue thermogenesis and 
inflammation. In order to adequately translate preclinical findings to future clinical trials, 
it is critical that mouse researchers are not biasing their findings by inappropriately 
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housing their mice. Taken together, by identifying the roles of adipose tissue Pik3r1 in 
regulating adipose tissue and systemic insulin sensitivity, the studies presented in this 
dissertation support the use of adipose tissue Pik3r1 as a therapeutic target for attenuating 
metabolic disease.  
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APPENDIX A 
 
FIGURES FOR CHAPTER I 
 
 
 
 
  
Figure 1. The protein domains of PI 3-Kinase regulatory subunits. The full length 
p85a gene products and p55a and p50a, contain the common SH2 carboxy-terminal 
domain, an internal SH2 domain and the p110 catalytic subunit binding domain. p50a and 
p55a lack the amino-terminal portion found in the full length p85a and p85b containing 
the SH3 domain, the proline-rich domains, and the BH domain, and in its place p55a and 
p50a have unique amino-terminal sequences consisting of 34 and 6 amino acids, 
respectively. 
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APPENDIX B 
 
FIGURES FOR CHAPTER II 
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Figure 1. Model validation, body weight, body composition and tissue weights in WT, 
HZ and KO mice fed a control diet vs. high fat diet for 3d. (A) Immunoblot of PI3K 
p85α abundance in eWAT of WT, HZ and KO mice (n = 3-5/group). (B) Body weight and 
(C) percent fat mass following 3d of CON and HFD treatment (n =15-20/group). (D) 
Inguinal scWAT, (E) perigondal eWAT and (F) interscapular BAT mass following 3d of 
CON and HFD feeding (n = 15-20/group). Data reported as mean ± SEM. # differences 
within same genotype (# P < 0.05; ## P < 0.01; ### P < 0.001; #### P < 0.0001). * 
differences within same diet (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001).
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Figure 2.
Figure 2. Metabolic phenotyping in WT, HZ and KO mice fed control diet vs. high fat 
diet for 3d. Food intake assessed during the (A) light and (B) dark cycles (n =10-15/group). 
(C) Respiratory exchange ratio (RER) assessed during the light and (D) dark cycles (n= 
10-15/group). (E) Total activity assessed during the light and (F) dark cycles (n= 10-15/
group). (G) Energy expenditure assessed during the light and (H) dark cycles (n =10-15/
group). Data reported as mean ± SEM. # differences within same genotype (# P < 0.05; ## P 
< 0.01; ### P < 0.001; #### P < 0.0001). * differences within same diet (* P < 0.05; ** P < 
0.01; *** P < 0.001; **** P < 0.0001).
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Figure 3. Perigonadal eWAT p85α abundance, glucose metabolism and insulin 
sensitivity in WT, HZ and KO mice fed control diet vs. high fat diet for 3d. (A) 
Perigonadal eWAT p85α abudance in WT mice fed CON or HFD for 3d (n = 6-7/group). 
(B) Fasting blood glucose in WT, HZ and KO mice fed CON or HFD for 3d (n = 20-30/
group). Oral glucose tolerance tests in (C) WT, (D) HZ and (E) KO mice fed CON or HFD 
for 3d (n = 10-15/group). (F) Oral glucose toleranc AUC in WT, HZ and KO mice fed CON 
or HFD for 3d (n = 10-15/group). Insulin tolerance tests in (G) WT, (H) HZ and (I) KO 
mice fed CON or HFD for 3d (n = 5-10/group). Data reported as mean ± SEM. # 
differences within same genotype (# P < 0.05; ## P < 0.01; ### P < 0.001; #### P < 
0.0001). * differences within same diet (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 
0.0001).
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Figure 1. Pik3r1 is knocked out strictly in adipocytes following administration 
of tamoxifen. p85 abundance from WT, HZ and KO mice in (A) WAT adipocytes, 
(B) WAT SVF, (C) gastrocnemius and (D) liver. Data reported as mean  SEM. CON, 
control diet; HFD, high fat diet. Significant between genotype differences are 
expressed with * (* P< 0.05, ** P<0.01, *** P<0.001, **** P<0.0001).
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A
Figure 2. Body weight and adiposity are inversely associated with adipocyte Pik3r1 
expression following 12 weeks of HFD feeding. (A) Illustration of study design, (B) body 
weight, (C) percent fast mass, (D) inguinal scWAT mass, (E) gonadal eWAT mass and (F) 
interscapular BAT mass. Data reported as mean  SEM. CON, control diet; HFD, high fat diet. 
Significant between diet differences are expressed with # (# P< 0.05, ## P<0.01, ### 
P<0.001, #### P<0.0001). Significant between genotype differences are expressed with *    
(* P< 0.05, ** P<0.01, *** P<0.001, **** P<0.0001).
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Figure 3. Metabolic phenotyping in WT, HZ and KO mice fed control diet vs. high fat . 
Food intake assessed during the (A) light and (B) dark cycles (n =10-15/group). (C) 
Respiratory exchange ratio (RER) assessed during the light and (D) dark cycles (n= 10-15/
group). (E) Total activity assessed during the light and (F) dark cycles (n= 10-15/group). (G) 
Energy expenditure assessed during the light and (H) dark cycles (n =10-15/group). Data 
reported as mean ± SEM. # differences within same genotype (# P < 0.05; ## P < 0.01; ### 
P < 0.001; #### P < 0.0001). * differences within same diet (* P < 0.05; ** P < 0.01; *** P 
< 0.001; **** P < 0.0001).
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Figure 4.
Figure 4. Glucose tolerance before and after heterozygous and homozygous Pik3r1
knockout. Oral glucose tolerance tests in CON and HFD fed (A) WT, (B) HZ and (C) KO 
mice prior to tamoxifen treatment. (D) Glucose area under the curve in CON and HFD fed 
WT, HZ and KO mice prior to tamoxifen treatment. Oral glucose tolerance tests in CON and 
HFD fed (E) WT, (F) HZ and (G) KO mice prior to tamoxifen treatment. (H) Glucose area 
under the curve in CON and HFD fed WT, HZ and KO mice following tamoxifen treatment. 
Data reported as mean  SEM. CON, control diet; HFD, high fat diet. Significant between diet 
differences are expressed with # (# P< 0.05, ## P<0.01, ### P<0.001, #### P<0.0001). 
Significant between genotype differences are expressed with *    (* P< 0.05, ** P<0.01, *** 
P<0.001, **** P<0.0001).
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Figure 5.  In vivo insulin tolerance and insulin-stimulated suppression of plasma 
glycerol. Insulin tolerance tests in CON and HFD fed (A) WT, (B) HZ and (C) KO mice 
following tamoxifen treatment, and I-stim glucose area above the curve (D) . (E) Insulin-
stimulated suppression of plasma glycerol in WT CON, WT HFD, HZ HFD and KO HFD. 
Data reported as mean  SEM. CON, control diet; HFD, high fat diet. Significant between 
diet differences are expressed with # (# P< 0.05, ## P<0.01, ### P<0.001, #### 
P<0.0001). Significant between genotype differences are expressed with *    (* P< 0.05, 
** P<0.01, *** P<0.001, **** P<0.0001).
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Figure 6. Adipocyte insulin signaling after heterozygous and homozygous KO of Pik3r1. 
(A) Representative immunoblots of pAKT(S473), pan AKT, pIRS1(Y896), total IRS1 and 
GAPDH. Quantification of (B) pIRS1(Y896), (C) total IRS1, (D) pAKT(S473) and (E) total 
Akt, quantified relative to GAPDH. Data reported as mean  SEM. CON, control diet; HFD, 
high fat diet. Significant between diet differences are expressed with # (# P < 0.05, ## P < 
0.01, ### P < 0.001, #### P < 0.0001) . Significant between genotype differences are 
expressed with * (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001).
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Figure 1. 
 
 
 
  
Figure 1. Design of adipocyte specific p55a OX mouse. Pik3r1 knock-in at the ROSA26 locus 
by recombinase-mediated cassette exchange (RMCE).  A Pik3r1 recombination cassette was 
made by flanking the cDNA of Pik3r1 (p85a, p55a or p50a) and a floxed PGK-Puro selection 
marker followed by 4x SV40 polyA STOP signal with FRT and F3.  This cassette together with 
pCAG-Flpe were electroporated into ROSA-FNF3-1F1 ES cells (an ES cell line targeted with 
FRT-PGK-neo-F3 at the ROSA26 locus).  The exchange of neo for Pik3r1 at the ROSA26 locus 
was facilitated by Flp-recombinase mediated site specific recombination so that the 
recombinants would become G418 sensitive and Puro resistant.  The correct exchange was 
confirmed by PCR.  The 4x SV40 polyA STOP signal along with the selection marker PGK-
Puro is removed by Cre recombinase.  This puts the Pik3r1 cDNA under the expression of the 
endogenous ROSA26 promoter.   
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Figure 2. Validation of adipocyte specific OX of p55. Body weight, body composition 
and adipose tissue weight in WT and adipo-p55OX mice. Representative mmunoblot and 
quantification of (A) eWAT p55α, (B) eWAT p85α, (C) BAT p55α, (D) Liver p55α and (E) 
Gastrocnemius p55α in WT and adipo-p55 OX mice. Data are expressed as means +  SEM. * 
represent significant differences between groups (* P < 0.05, ** P < 0.01, *** P < 0.001, 
**** P < 0.0001). (n= 5-6/ group).
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Figure 3. Body weight, body composition and adiposity in WT and p55α OX mice. (A) 
Body weight, (B) percent fat mass, (C) inguinal scWAT, (D) perigonadal eWAT, (E)  
interscapular BAT in male WT and adipo-p55OX mice. Data are expressed as means + SEM. 
* represent significant differences between groups (* P < 0.05, ** P < 0.01, *** P < 0.001, 
**** P < 0.0001). (n= 10-15/ group).
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Figure 4. The effect of adipocyte specific p55 OX on Kilocalories consumed, substrate 
utilization, activity and energy expenditure in WT and adipo-p55 OX mice. (A) Food 
intake, (B) respiratory exchange ratio, (C) total activity and (D) energy expenditure during 
the light and dark cycles in male WT and adipo-p55OX mice. Data are expressed as means 
+ SEM. # represent between cycle differences (# P < 0.05, ## P < 0.01, ### P < 0.001, 
#### P < 0.0001). * represent significant differences between groups (* P < 0.05, ** P < 
0.01, *** P < 0.001, **** P < 0.0001). (n= 10-12/ group).
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Figure 5. The effect of adipocyte specific p55 OX on glucose tolerance, systemic insulin 
sensitivity and adipocyte insulin sensitivity. (A) Oral glucose tolerance tests, (B) glucose 
area under the curve, (C) insulin tolerance tests and (D) insulin-stimulated suppression of 
plasma glycerol in WT and adipo-p55OX mice. Data are expressed as means + SEM. * 
represent significant differences between groups (* P < 0.05, ** P < 0.01, *** P < 0.001, 
**** P < 0.0001)
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Figure 6. Perigonadal eWAT insulin signaling in WT and adipocyte specific p55 OX 
mice. Insulin stimulated (A) phospho-IRS1(Y896), (B) phospho-AKT(S473), (C) total 
IRS-1 and (D) Total Akt in basal and insulin stimulated perigondadal eWAT of WT and 
adipo-p55OX mice. Data reported as means + SEM.
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Figure 7. Thermogenic programming of BAT in WT and mice with adipocyte 
specific p55α OX. Brown adipose tissue (A) Ucp1 gene expression, (B) UCP1 protein 
abundance, (C) Prdm16 gene expression and (D) PRDM16 protein abundance. Data are 
expressed as means + SEM. * represent between group differences (* P < 0.05, ** P < 
0.01, *** P < 0.001, P < 0.0001.
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Fig. 1. Body weight and adiposity are increased in WT mice housed at murine 
thermoneutral temperature (30°C) vs. standard vivarium temperature (22°C) independent 
of diet. (A) Illustration of the study design. (B) p85 abundance in scWAT from Pik3r1flox/flox 
mice and C57BL6/J mice. (C) p85 abundance in eWAT from Pik3r1flox/flox mice and C57BL6/J 
mice. (D) Body weight and body composition before and after 1d CON, 1d HFD and 5d HFD  
treatment at standard vivarium temperature (22°C) (n=35/group) and murine thermoneutral 
temperature (30°C) (n =20/group). Inguinal scWAT (E), eWAT (F) and BAT (G) weight following 
1 or 5d of CON and HFD feeding at 22°C (n = 35/group) and 30°C (n = 20/group). Data were 
analyzed by a 2-way ANOVA (diet x temperature) with a Sidak multiple comparison test.  p-
values for main effects (p≤0.01) are listed in each graph.  Significant findings with multiple 
comparison test for temperature are indicated with # (# p<0.05, ## p<0.01, ### p<0.001, #### 
p<0.0001) and for diet are indicated with * (*p< 0.05, ** p<0.01, *** p<0.001, **** p<0.0001).
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Fig. 2. Housing temperature alters the metabolic phenotype of mice on a control and 
high fat diet. Food intake assessed during the light (A) and dark cycles (B) during 1d CON, 
1d HFD and 5d HFD at 22°C (n =10/group) and 30°C (n= 15/group). Respiratory exchange 
ratio (RER) assessed during the light (C) and dark cycles (D) during 1d CON, 1d HFD and 5d 
HFD at 22°C (n= 10/group) and 30°C (n= 15/group). Total activity assessed during the light 
(E) and dark (F) cycles during 1d CON, 1d HFD and 5d HFD at 22°C (n= 10/group) and 30°C 
(n= 15/group). Energy expenditure assessed during the light (G) and dark cycles (H) during 1d 
CON, 1d HFD and 5d HFD at 22°C (n =10/group) and 30°C (n =15/group). Data reported as 
mean ± SEM. CON, control diet; HFD, high fat diet.  Data were analyzed by a 2-way ANOVA 
(diet x temperature) with a Sidak multiple comparison test.  p-values for main effects (p≤0.01) 
are listed in each graph.  Significant findings with multiple comparison test for temperature are 
indicated with # (# p<0.05, ## p<0.01, ### p<0.001, #### p<0.0001) and for diet are indicated 
with * (*p< 0.05, ** p<0.01, *** p<0.001, **** p<0.0001).
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Fig. 3. Short-term thermoneutral housing alters on glucose homeostasis and insulin 
sensitivity in response to a high fat diet. (A) Fasting (4h) glucose following 1d CON, 1d HFD 
and 5d HFD treatment at standard vivarium temperature (22°C) (n = 20/group) and murine 
thermoneutral temperature (30°C) (n =15/group). (B-C) Oral glucose tolerance and glucose AUC 
(D) following 1d or 5d of CON and HFD treatment at standard vivarium temperature (22°C) (n= 
17/group) and murine thermoneutral temperature (30°C) (n = 15/group). (E-F) Insulin tolerance 
tests following 1 (E) or 5d (F) of CON and HFD at 22°C (n =8/group) and 30°C (n=7/group) 
housing temperatures. (G-H) In vivo 3H-2-deoxy-d-glucose uptake following 1d of CON or HFD 
diet at 22°C (n =5/group) (E) and 30°C (n = 5/group) housing temperatures. Data reported as 
mean ± SEM. CON, control diet; HFD, high fat diet.  Data were analyzed by a 2-way ANOVA 
(diet x temperature) with a Sidak multiple comparison test.  p-values for main effects (p≤0.01) are 
listed in each graph.  Significant findings with multiple comparison test for temperature are 
indicated with # (# p<0.05, ## p<0.01, ### p<0.001, #### p<0.0001) and for diet are indicated 
with * (*p< 0.05, ** p<0.01, *** p<0.001, **** p<0.0001).
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Fig. 4.  Short-term thermoneutral housing reduces gene expression markers of 
thermogenesis in BAT. (A) Ucp1, (B) Prdm16, (C) Cox8b, and (D) Pgc1a following 1d CON, 1d 
HFD, 5d CON and 5d HFD treatment at standard vivarium temperature (22°C) and murine 
thermoneutral temperature (30°C). (E) Immunoblots and quantification of (F) PRDM16 and (G) 
UCP-1 abundance in BAT. Data reported as mean ± SEM. CON, control diet; HFD, high fat diet.  
Data were analyzed by a 2-way ANOVA (diet x temperature) with a Sidak multiple comparison 
test.  p-values for main effects (p≤0.01) are listed in each graph.  Significant findings with multiple 
comparison test for temperature are indicated with # (# p<0.05, ## p<0.01, ### p<0.001, #### 
p<0.0001) and for diet are indicated with * (*p< 0.05, ** p<0.01, *** p<0.001, **** p<0.0001).
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Figure 5.
Fig. 5. Short-term thermoneutral housing reduces activation of browning genes in 
inguinal scWAT. (A) Ucp1, (B) Cox8b, (C) Cidea, and (D) Pgc1a following 1d CON, 1d 
HFD, 5d CON and 5d HFD treatment at standard vivarium temperature (22°C) and murine 
thermoneutral temperature (30°C). Data reported as mean ± SEM. CON, control diet; HFD, 
high fat diet. Data were analyzed by a 2-way ANOVA (diet x temperature) with a Sidak 
multiple comparison test.  p-values for main effects (p≤0.01) are listed in each graph.  
Significant findings with multiple comparison test for temperature are indicated with # (# 
p<0.05, ## p<0.01, ### p<0.001, #### p<0.0001) and for diet are indicated with * (*p< 0.05, 
** p<0.01, *** p<0.001, **** p<0.0001).
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F
Fig. 6. Short-term thermoneutral housing reduces inguinal scWAT anti-inflammatory 
gene expression in response to high fat diet. scWAT (A) and eWAT (B) Il4 gene 
expression, scWAT (C) and eWAT (D) Il10 gene expression, and scWAT (E) and eWAT (F) 
Il13 gene expression following 1d CON, 1d HFD, 5d CON and 5d HFD treatment at 
standard vivarium temperature (22°C) and murine thermoneutral temperature (30°C). Data 
reported as mean ± SEM. CON, control diet; HFD, high fat diet.  Significant findings with 
multiple comparison test for temperature are indicated with # (# p<0.05, ## p<0.01, ### 
p<0.001, #### p<0.0001) and for diet are indicated with * (*p< 0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001).
	 104 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
22°C 30°C
0
0.6
0.8
1.0
1.2
1.4
1.6
eW
AT
Il6
 m
R
N
A 
Ex
pr
es
si
on
(R
el
at
iv
e 
to
 B
et
a 
A
ct
in
)
Diet: P = 0.005
Temp: NS
**
22°C 30°C
0
0.6
0.8
1.0
1.2
1.4
1.6 Diet: P = 0.002
Temp: NS
*
22°C 30°C
0
0.6
0.8
1.0
1.2
1.4
1.6 Diet: P = 0.0003
Temp: P = 0.0006
##
**
22°C 30°C
0
0.6
0.8
1.0
1.2
1.4
1.6
eW
AT
C
cl
2 
m
R
N
A 
Ex
pr
es
si
on
(R
el
at
iv
e 
to
 B
et
a 
A
ct
in
)
Diet: P = NS (0.02)
Temp: NS
22°C 30°C
0.0
0.6
0.8
1.0
1.2
1.4
1.6
eW
AT
Tn
fa
m
RN
A
Ex
pr
es
si
on
(R
el
at
iv
e
to
Be
ta
Ac
tin
)
Diet: NS
Temp: NS
1d CON
1d HFD
22°C 30°C
0.0
0.6
0.8
1.0
1.2
1.4
1.6 5d CON
5d HFD
Diet: NS
Temp: NS
22°C 30°C
0
0.6
0.8
1.0
1.2
1.4
1.6
eW
AT
Il1
b 
m
R
N
A 
Ex
pr
es
si
on
(R
el
at
iv
e 
to
 B
et
a 
A
ct
in
)
Diet: P = 0.0008
Temp: NS
**
22°C 30°C
0
0.6
0.8
1.0
1.2
1.4
1.6 Diet: NS (0.02)
Temp: NS
C D
Figure 7.
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Fig. 7. Standard vivarium housing temperature (22°C) but not thermoneutral housing 
increases eWAT pro-inflammatory gene expression in response to a HFD.  eWAT (A) 
Tnfa, (B) Il1b, (C) Il6, and (D) Ccl2 gene expression following 1d CON, 1d HFD, 5d CON 
and 5d HFD at standard vivarium temperature (22°C) and murine thermoneutral temperature 
(30°C). Data reported as mean ± SEM. CON, control diet; HFD, high fat diet.  Significant 
findings with multiple comparison test for temperature are indicated with # (# p<0.05, ## 
p<0.01, ### p<0.001, #### p<0.0001) and for diet are indicated with * (*p< 0.05, ** p<0.01, 
*** p<0.001, **** p<0.0001). 
	 105 
APPENDIX F 
 
FIGURE FOR CONCLUSION 
 
 
 
Figure 1. Proposed mechanism as to how PI3K is influencing thermogenesis in brown 
adipose tissue (BAT). PI3K catalyzes the reaction of phosphatidylinositol 4-5, bisphosphate 
(PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3). Upon activation of PIP3, protein kinase 
3-phosphoinositide dependent protein kinase-1 (PDK1) is recruited to the plasma membrane and 
activated, which phosphorylates AKT1 at Serine473 and AKT2 at Serine474. Upon PIP3 
activation, mammalian target of rapamycin complex 2 (mTORC2) is also recruited to the plasma 
membrane and activated, and phosphorylates AKT1 at Threonine308 (4). mTORC2 activation of 
AKT1 phosphorylation has been shown to increase with cold exposure, and mice with adipose 
tissue specific knockout of mTORC2 have impaired cold-induced thermogenesis, upregulation of 
Ucp1 and decreased BAT glucose uptake (1). Furthermore, BAT AKT2 phosphorylation is 
increased during thermal stress in mice, which activates Carbohydrate-responsive element 
binding protein (ChREBP), and its conversion from the a to b isoform enhances mitochondrial 
fatty acid oxidation in BAT (10). 
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